

Access DB# \_\_\_\_\_

## SEARCH REQUEST FORM

### Scientific and Technical Information Center

Requester's Full Name: MURRAY HUDET Examiner #: 79808 Date: 3/7/03  
Art Unit: 1654 Phone Number 305-5039 Serial Number: 09/719423  
Mail-Box and Bldg/Room Location: 11D13 Results Format Preferred (circle): PAPER  DISK  E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: 6-12-98

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

rT3 to (covalently) by (a) / the (B1) / INSULIN specifically,  
‡ rT3 covalently bound insulin, ‡

Conjug. of rT3 & insulin

S2

Follow-up

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher: <u>Harley</u>		NA Sequence (#)	STN <u>\$243</u>
Searcher Phone #:		AA Sequence (#)	Dialog _____
Searcher Location:		Structure (#)	Questel/Orbit _____
Date Searcher Picked Up:	<u>3/7</u>	Bibliographic	Dr. Link _____
Date Completed:	<u>3/7</u>	Litigation	Lexis/Nexis _____
Searcher Prep & Review Time:		Fulltext	Sequence Systems _____
Clerical Prep Time:		Patent Family	WWW/Internet _____
Online Time:	<u>32 min</u>	Other	Other (specify) _____

09/719;423

FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003

E INSULIN/CN  
E INSULIN (HUMAN) /CN  
L33 3 S E272,E32,E96  
SELECT RN L33 1-3  
L34 31 S E282-284/CRN  
L35 6509 S "INSULIN"  
L36 0 S L35 AND RT3/NTE  
L37 0 S L35 AND "RT3"  
L38 0 S L35 AND NTE/FS  
L39 4027 S L35 AND NTE/FA  
L40 0 S L39 AND "RT3"  
L41 18 S "RT3"  
L42 1 S L41 AND C15 H12 I3 N 04/MF

FILE 'CAPLUS' ENTERED AT 15:07:36 ON 07 MAR 2003

L43 1514 S L42  
L44 82 S L43(L) (RRT OR RCT) /RL  
L45 0 S L44 AND INSULIN  
L46 35 S L43 AND INSULIN/IT  
L47 2 S L46 AND CONJUG?  
L48 60 S L43 AND INSULIN  
L49 2 S L48 AND CONJUGAT?  
L50 2 S L48 AND LINK?  
L51 0 S L48 AND COVALENT?  
L52 3 S L48 AND REACT?  
L53 52 S INSULIN AND RT3  
L54 1 S L53 AND CONJUGAT?  
L55 7 S L53 AND (LINK? OR COVALENT? OR REACT?)  
L56 16982 S ?TRIIODOTHYRONINE?  
L57 1569 S L56 AND INSULIN  
L58 1569 S L56 AND L57  
L59 14 S L58 AND CONJUGAT?  
L60 5 S L58 AND CONJUGAT?/IT  
L61 1 S 1999:811275/AN  
SELECT RN L61 1

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 MAR 2003

L62 3 S E285-287

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:24:46 ON 07 MAR 2003

L63 1 S 252878-62-9  
L64 6064 S INSULIN AND (RT3 OR ?TRIIODOTHYRONIN? )  
L65 39 S L64 AND CONJUGAT?

FILE 'STNGUIDE' ENTERED AT 15:28:51 ON 07 MAR 2003

=> d cost COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.00	92.90
NETWORK CHARGES	0.06	6.06
SEARCH CHARGES	0.00	89.06
DISPLAY CHARGES	0.00	55.36
	-----	-----
CAPLUS FEE (5%)	0.06	243.38
	0.00	8.05
	-----	-----

09/719,423

FULL ESTIMATED COST	0.06	251.43
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-5.85

IN FILE 'STNGUIDE' AT 15:29:41 ON 07 MAR 2003

=>

09/719, 423

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'HCAPLUS' AT 14:49:22 ON 07 MAR 2003  
FILE 'HCAPLUS' ENTERED AT 14:49:22 ON 07 MAR 2003  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> file reg  
FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2003 HIGHEST RN 497140-34-8  
DICTIONARY FILE UPDATES: 6 MAR 2003 HIGHEST RN 497140-34-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e insulin/cn  
E30 1 INSULFAB KP 121/CN  
E31 1 INSULICOLIDE A/CN  
E32 1 --> INSULIN/CN  
E33 1 INSULIN (29-DE-LYSINE) (HUMAN B-CHAIN) FUSION PROTEIN WITH S  
YNTHETIC TRIPEPTIDE FUSION PROTEIN WITH INSULIN (HUMAN A-CHA  
IN)/CN  
E34 1 INSULIN (A20A-GLYCINE, B30A-ARGININE, B30B-ARGININE) (HUMAN) /C  
N  
E35 1 INSULIN (A21-ALANINE) (HUMAN) /CN  
E36 1 INSULIN (A21-ALANINE, B3-GLUTAMINE) (HUMAN) /CN  
E37 1 INSULIN (A21-GLYCINE) (HUMAN) /CN  
E38 1 INSULIN (A21-GLYCINE, B3-GLUTAMINE) (HUMAN) /CN  
E39 1 INSULIN (A21-GLYCINE, B31-ARGININE, B32-ARGININE) (HUMAN) /CN  
E40 1 INSULIN (AFRICAN LUNGFISH A-CHAIN) /CN  
E41 1 INSULIN (AFRICAN LUNGFISH B-CHAIN) /CN  
  
=> e  
E42 1 INSULIN (ALLIGATOR MISSISSIPPIENSIS) /CN  
E43 1 INSULIN (ALLIGATOR MISSISSIPPIENSIS-A REDUCED) /CN  
E44 1 INSULIN (ALLIGATOR MISSISSIPPIENSIS-B REDUCED) /CN  
E45 1 INSULIN (ALOPEX LAGOPUS) /CN  
E46 1 INSULIN (AMIA CALVA) /CN  
E47 1 INSULIN (AMIA CALVA-A REDUCED) /CN  
E48 1 INSULIN (AMIA CALVA-B REDUCED) /CN  
E49 1 INSULIN (AMPHIUMA TRIDACTYLYM A-CHAIN REDUCED) /CN  
E50 1 INSULIN (AMPHIUMA TRIDACTYLYM B-CHAIN REDUCED) /CN  
E51 1 INSULIN (AMPHIUMA TRIDACTYLYM-A REDUCED) /CN

E52 1 INSULIN (AMPHIUMA TRIDACTYLUM-B REDUCED) /CN  
 E53 1 INSULIN (ANGUILLA JAPONICA) /CN

=> e

E54 1 INSULIN (ANGUILLA JAPONICA-A REDUCED) /CN  
 E55 1 INSULIN (ANGUILLA JAPONICA-B REDUCED) /CN  
 E56 1 INSULIN (ANGUILLA ROSTRATA) /CN  
 E57 1 INSULIN (AOTUS TRIVIRGATUS) /CN  
 E58 1 INSULIN (AOTUS TRIVIRGATUS-A REDUCED) /CN  
 E59 1 INSULIN (AOTUS TRIVIRGATUS-B REDUCED) /CN  
 E60 1 INSULIN (APLYSIA CALIFORNICA-A REDUCED) /CN  
 E61 1 INSULIN (APLYSIA CALIFORNICA-B REDUCED) /CN  
 E62 1 INSULIN (B1-ASPARTIC ACID, B13-GLUTAMIC ACID) (HUMAN) /CN  
 E63 1 INSULIN (B1-ASPARTIC ACID, B13-GLUTAMINE) (HUMAN) /CN  
 E64 1 INSULIN (B10-GLUTAMIC ACID) (HUMAN) FUSION PROTEIN WITH INSULIN-LIKE GROWTH FACTOR I (HUMAN C-DOMAIN) /CN  
 E65 1 INSULIN (B28-ALANINE) (HUMAN) /CN

=> e

E66 1 INSULIN (B28-ALANINE, B29-PROLINE) (HUMAN) /CN  
 E67 1 INSULIN (B28-ASPARTIC ACID) (HUMAN) /CN  
 E68 1 INSULIN (B28-ASPARTIC ACID, B29-PROLINE) (HUMAN) /CN  
 E69 1 INSULIN (B28-LEUCINE) (HUMAN) /CN  
 E70 1 INSULIN (B28-LEUCINE, B29-PROLINE) (HUMAN) /CN  
 E71 1 INSULIN (B28-LYSINE) (HUMAN) /CN  
 E72 1 INSULIN (B28-LYSINE, B29-PROLINE) (HUMAN) /CN  
 E73 1 INSULIN (B28-VALINE) (HUMAN) /CN  
 E74 1 INSULIN (B28-VALINE, B29-PROLINE) (HUMAN) /CN  
 E75 1 INSULIN (B3-GLUTAMINE) (HUMAN) /CN  
 E76 1 INSULIN (B30-GLUTAMINE) (HUMAN) /CN  
 E77 1 INSULIN (B31-ARGININE, B32-ARGININE) (HUMAN) /CN

=> e

E78 1 INSULIN (B32A-ARGININE) (SYNTHETIC HUMAN CLONE PINT302) /CN  
 E79 1 INSULIN (B34A-ARGININE) (SYNTHETIC HUMAN CLONE PINT316) /CN  
 E80 1 INSULIN (BEEF) /CN  
 E81 1 INSULIN (BISON BONASUS) /CN  
 E82 1 INSULIN (BOVINE) /CN  
 E83 1 INSULIN (BUFO MARINUS-A REDUCED) /CN  
 E84 1 INSULIN (BUFO MARINUS-B REDUCED) /CN  
 E85 1 INSULIN (CAENORHABDITIS ELEGANS ISOFORM 1) /CN  
 E86 1 INSULIN (CAENORHABDITIS ELEGANS ISOFORM 2) /CN  
 E87 1 INSULIN (CALLORHYNCHUS CALLORHYNCHUS) /CN  
 E88 1 INSULIN (CANIS FAMILIARIS) /CN  
 E89 1 INSULIN (CANIS FAMILIARIS-A REDUCED) /CN

=> e

E90 1 INSULIN (CANIS FAMILIARIS-B REDUCED) /CN  
 E91 1 INSULIN (CANIS FAMILIARIS-B REDUCED), BIMOL. CYCLIC (7.FWDARW.19'), (19.FWDARW.7')-BIS(DISULFIDE) /CN  
 E92 1 INSULIN (CASIRAGUA) /CN  
 E93 1 INSULIN (CASIRAGUA-A REDUCED) /CN  
 E94 1 INSULIN (CASIRAGUA-B REDUCED) /CN  
 E95 1 INSULIN (CATTLE CLONE INS10 B CHAIN) FUSION PROTEIN WITH PEP TIDE (SYNTHETIC CLONE INS10) FUSION PROTEIN WITH INSULIN (CATTLE CLONE INS10 A CHAIN) /CN  
 E96 1 INSULIN (CATTLE) /CN  
 E97 1 INSULIN (CATTLE), (SECO-8B/9B)- (CATTLE) /CN  
 E98 1 INSULIN (CATTLE), 10A-L-ISOLEUCINE-16B-L-GLUTAMINE-17B-L-PHE

NYLALANINE-30B-L-THREONINE-/CN

E99 1 INSULIN (CATTLE), 10A-L-ISOLEUCINE-30B-L-THREONINE-/CN

E100 1 INSULIN (CATTLE), 10B-L-ASPARTIC ACID-16B-L-PHENYLALANINE-26  
B-L-PHENYLALANINE-/CN

E101 1 INSULIN (CATTLE), 10B-L-ASPARTIC ACID-30B-L-THREONINE-/CN.

=> e

E102 1 INSULIN (CATTLE), 11B-L-VALINE-12B-L-LEUCINE-/CN

E103 1 INSULIN (CATTLE), 12B-(2-METHYLALANINE)-/CN

E104 1 INSULIN (CATTLE), 12B-D-ALANINE-/CN

E105 1 INSULIN (CATTLE), 12B-L-ISOLEUCINE-30B-L-THREONINE-/CN

E106 1 INSULIN (CATTLE), 12B-L-PHENYLALANINE-/CN

E107 1 INSULIN (CATTLE), 14-(O-(1-METHYLPYRIDINIUM-2-YL)-L-TYROSINE  
)-, INNER SALT/CN

E108 1 INSULIN (CATTLE), 14A,16B,19A,26B-TETRAKIS(HYDROGEN SULFATE)  
/CN

E109 1 INSULIN (CATTLE), 14A-(3-(IODO-123I)-L-TYROSINE)-/CN

E110 1 INSULIN (CATTLE), 14A-(3-(IODO-125I)-L-TYROSINE)-/CN

E111 1 INSULIN (CATTLE), 14A-(3-(IODO-125I)-L-TYROSINE)-29B-(N6-(4-  
AZIDOBENZOYL)-L-LYSINE)-/CN

E112 1 INSULIN (CATTLE), 14A-(3-IODO-L-TYROSINE)-/CN

E113 1 INSULIN (CATTLE), 14A-(3-NITRO-L-TYROSINE)-16B-(3-NITRO-L-TY  
ROSINE)-19A-(3-NITRO-L-TYROSINE)-26B-(3-NITRO-L-TYROSINE)-/C  
N

=> e

E114 1 INSULIN (CATTLE), 14A-(O-(1-METHYLPYRIDINIUM-2-YL)-L-TYROSIN  
E)-/CN

E115 1 INSULIN (CATTLE), 14A-(O-(2-NITRO-4-(TRIMETHYLAMMONIO)PHENYL  
)-L-TYROSINE)-/CN

E116 1 INSULIN (CATTLE), 14A-(O-(2-NITRO-4-(TRIMETHYLAMMONIO)PHENYL  
)-L-TYROSINE)-, IODIDE/CN

E117 1 INSULIN (CATTLE), 15A-L-ASPARAGINE-17A-L-PROLINE-21A-L-ALANI  
NE-/CN

E118 1 INSULIN (CATTLE), 15B-L-ALANINE-16B-L-ALANINE-/CN

E119 1 INSULIN (CATTLE), 16B-(O-(1-METHYLPYRIDINIUM-2-YL)-L-TYROSIN  
E)-, INNER SALT/CN

E120 1 INSULIN (CATTLE), 16B-L-ALANINE-/CN

E121 1 INSULIN (CATTLE), 16B-L-PHENYLALANINE-/CN

E122 1 INSULIN (CATTLE), 16B-L-PHENYLALANINE-26B-L-PHENYLALANINE-/C  
N

E123 1 INSULIN (CATTLE), 16B-L-TRYPTOPHAN-30B-L-THREONINE-/CN

E124 1 INSULIN (CATTLE), 19A-(O-(1-METHYLPYRIDINIUM-2-YL)-L-TYROSIN  
E)-, INNER SALT/CN

E125 1 INSULIN (CATTLE), 1A-(N-((1,1-DIMETHYLETHOXY)CARBONYL)-D-ALA  
NINE)-1B-(N-((1,1-DIMETHYLETHOXY)CARBONYL)-D-ALANINE)-/CN

=> e

E126 1 INSULIN (CATTLE), 1A-(N-((1,1-DIMETHYLETHOXY)CARBONYL)-L-TRY  
PTOPHAN)-/CN

E127 1 INSULIN (CATTLE), 1A-(N-((1,1-DIMETHYLETHOXY)CARBONYL)-L-VAL  
INE)-/CN

E128 1 INSULIN (CATTLE), 1A-(N-(2,7-DIAMINO-7-CARBOXY-1-OXOHEPTYL)-  
D-ALANINE)-1B-D-ALANINE-, CYCLIC (1A.FWDARW.29B)-PEPTIDE/CN

E129 1 INSULIN (CATTLE), 1A-(N4-((4-AZIDOPHENYL)ACETYL)-D-2,4-DIAMI  
NOBUTANOIC ACID)-/CN

E130 1 INSULIN (CATTLE), 1A-.BETA.-ALANINE-/CN

E131 1 INSULIN (CATTLE), 1A-D-ALANINE-1B-D-ALANINE-/CN

E132 1 INSULIN (CATTLE), 1A-D-ALANINE-26B-DE-L-TYROSINE-27B-DE-L-TH

REONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/C  
N

E133 1 INSULIN (CATTLE), 1A-D-ALANINE-9A-GLYCINE-/CN  
E134 1 INSULIN (CATTLE), 1A-D-GLUTAMIC ACID-/CN  
E135 1 INSULIN (CATTLE), 1A-D-LEUCINE-/CN  
E136 1 INSULIN (CATTLE), 1A-D-LYSINE-/CN  
E137 1 INSULIN (CATTLE), 1A-D-PHENYLALANINE-/CN

=> e

E138 1 INSULIN (CATTLE), 1A-D-PROLINE-/CN  
E139 1 INSULIN (CATTLE), 1A-D-SERINE-/CN  
E140 1 INSULIN (CATTLE), 1A-D-TRYPTOPHAN-/CN  
E141 1 INSULIN (CATTLE), 1A-DEGLYCINE-/CN  
E142 1 INSULIN (CATTLE), 1A-DEGLYCINE-1B-DE-L-PHENYLALANINE-/CN  
E143 1 INSULIN (CATTLE), 1A-DEGLYCINE-1B-DE-L-PHENYLALANINE-29B- (N6  
-((PHENYLAMINO)THIOXOMETHYL)-L-LYSINE)-/CN  
E144 1 INSULIN (CATTLE), 1A-DEGLYCINE-1B-DE-L-PHENYLALANINE-2A- (N-  
(1,3-DIHYDRO-1,3-DIOXO-2H-ISOINDOL-2-YL)ACETYL)-L-ISOLEUCINE  
)-2B- (N-(2-(1,3-DIHYDRO-1,3-DIOXO-2H-ISOINDOL-2-YL)-1-OXO-3-  
PHENYLPROPYL)-L-VALI/CN  
E145 1 INSULIN (CATTLE), 1A-DEGLYCINE-1B-DE-L-PHENYLALANINE-2A-DE-L  
-ISOLEUCINE-2B-DE-L-VALINE-/CN  
E146 1 INSULIN (CATTLE), 1A-DEGLYCINE-26B-DE-L-TYROSINE-27B-DE-L-TH  
REONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/C  
N  
E147 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- ((1,1-DIMETHYLETHOXY)AC  
ETYL)-L-ISOLEUCINE)-/CN  
E148 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- ((2,5-DIHYDRO-3-METHYL-  
2,5-DIOXO-1H-PYRROL-1-YL)ACETYL)-L-ISOLEUCINE)-/CN  
E149 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- ((PHENYLAMINO)THIOXOMET  
HYL)-L-ISOLEUCINE)-/CN

=> e

E150 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- ((TRIMETHYLMONIO)ACET  
YL)-L-ISOLEUCINE)-/CN  
E151 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- (1-OXOPROPYL)-L-ISOLEUC  
INE)-/CN  
E152 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- (4-AMINO-1-OXOBUTYL)-L-  
ISOLEUCINE)-/CN  
E153 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- (6-AMINO-1-OXOHEXYL)-L-  
ISOLEUCINE)-/CN  
E154 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N- (HYDROXYACETYL)-L-ISOLE  
UCINE)-/CN  
E155 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N-ACETYL-L-ISOLEUCINE)-/C  
N  
E156 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A- (N-ACETYL-L-ISOLEUCINE)-9A  
-GLYCINE-/CN  
E157 1 INSULIN (CATTLE), 1A-DEGLYCINE-2A-DE-L-ISOLEUCINE-3A-DE-L-VA  
LINE-4A-DE-L-GLUTAMIC ACID-9A-GLYCINE-/CN  
E158 1 INSULIN (CATTLE), 1A-DEGLYCINE-9A-GLYCINE-/CN  
E159 1 INSULIN (CATTLE), 1A-L-ALANINE-26B-DE-L-TYROSINE-27B-DE-L-TH  
REONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/C  
N  
E160 1 INSULIN (CATTLE), 1A-L-ALANINE-9A-GLYCINE-/CN  
E161 1 INSULIN (CATTLE), 1A-L-GLUTAMIC ACID-/CN

=> e

E162 1 INSULIN (CATTLE), 1A-L-LEUCINE-/CN  
E163 1 INSULIN (CATTLE), 1A-L-LYSINE-/CN

E164 1 INSULIN (CATTLE), 1A-L-PROLINE-/CN  
 E165 1 INSULIN (CATTLE), 1A-L-TRYPTOPHAN-/CN  
 E166 1 INSULIN (CATTLE), 1A-L-VALINE-/CN  
 E167 1 INSULIN (CATTLE), 1B-(4-AZIDO-L-PHENYLALANINE)-/CN  
 E168 1 INSULIN (CATTLE), 1B-(4-IODO-L-PHENYLALANINE)-/CN  
 E169 1 INSULIN (CATTLE), 1B-(L-PHENYL-T5-ALANINE)-/CN  
 E170 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-/CN  
 E171 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN  
 E172 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-(N-((4-AZIDO-2-NITROPHENYL)ACETYL)-L-VALINE)-/CN  
 E173 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-(N-(1-OXO-3-PHENYLPROPYL)-L-VALINE)-/CN

=> e

E174 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-(N-(2-(2,5-DIOXO-1-PYRROLIDINYL)-1-OXO-3-PHENYLPROPYL)-L-VALINE)-29B-(6-(2,5-DIOXO-1-PYRROLIDINYL)-L-NORLEUCINE)-, (S)-/CN  
 E175 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-(N-(3-(4-HYDROXY-3,5-DIIODOPHENYL)-1-OXOPROPYL)-L-VALINE)-/CN  
 E176 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-(N-(3-(4-HYDROXY-3-(IODO-125I)PHENYL)-1-OXOPROPYL)-L-VALINE)-/CN  
 E177 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-(N-(3-(4-HYDROXY-3-IODOPHENYL)-1-OXOPROPYL)-L-VALINE)-/CN  
 E178 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-/CN  
 E179 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN  
 E180 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-/CN  
 E181 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN  
 E182 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-(5-OXO-L-PROLINE)-/CN  
 E183 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-DE-L-GLUTAMINE-/CN  
 E184 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-DE-L-GLUTAMINE-5B-DE-L-HISTIDINE-/CN  
 E185 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-DE-L-GLUTAMINE-5B-DE-L-HISTIDINE-6B-DE-L-LEUCINE-/CN

=> e

E186 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-L-ALANINE-/CN  
 E187 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-L-ALANINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-/CN  
 E188 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-L-ALANINE-6B-L-VALINE-9B-L-ALANINE-10B-L-ALANINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-/CN  
 E189 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-DE-L-ASPARAGINE-4B-L-ALANINE-9B-L-ALANINE-10B-L-ALANINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-/CN  
 E190 1 INSULIN (CATTLE), 1B-DE-L-PHENYLALANINE-2B-DE-L-VALINE-3B-L-ASPARAGINE-4B-DE-L-GLUTAMINE-5B-DE-L-HISTIDINE-/CN

E191 1 INSULIN (CATTLE), 1B-L-ALANINE-2B-L-ALANINE-8A-L-HISTIDINE-9  
A-L-ASPARAGINE-10A-L-THREONINE-21A-DE-L-ASPARAGINE-27B-L-SER  
INE-30B-DE-L-ALANINE-/CN

E192 1 INSULIN (CATTLE), 1B-L-TRYPTOPHAN-/CN

E193 1 INSULIN (CATTLE), 21A-DE-L-ASPARAGINE-30B-DE-L-ALANINE-/CN

E194 1 INSULIN (CATTLE), 21A-L-ASPARTIC ACID-/CN

E195 1 INSULIN (CATTLE), 21A-L-ASPARTIC ACID-27B-L-GLUTAMIC ACID-30  
B-L-THREONINE-/CN

E196 1 INSULIN (CATTLE), 21B-(2-METHYLALANINE)-/CN

E197 1 INSULIN (CATTLE), 21B-D-GLUTAMIC ACID-/CN

=> e

E198 1 INSULIN (CATTLE), 21B-L-PROLINE-30B-L-THREONINE-/CN

E199 1 INSULIN (CATTLE), 22B-(2-METHYLALANINE)-/CN

E200 1 INSULIN (CATTLE), 22B-(N5-(3A,4,5,6,7,7A-HEXAHYDRO-3A,7A-DIH  
YDROXY-1H-BENZIMIDAZOL-2-YL)-L-ORNITHINE)-/CN

E201 1 INSULIN (CATTLE), 22B-(N5-(3A,4,5,6,7,7A-HEXAHYDRO-3A,7A-DIH  
YDROXY-1H-BENZIMIDAZOL-2-YL)-L-ORNITHINE)-, ZINC SALT/CN

E202 1 INSULIN (CATTLE), 22B-(N5-(3A,4,5,6,7,7A-HEXAHYDRO-3A,7A-DIH  
YDROXY-1H-BENZIMIDAZOL-2-YL)-L-ORNITHINE)-30B-DE-L-ALANINE-/CN

E203 1 INSULIN (CATTLE), 22B-(N5-(3A,4,5,6,7,7A-HEXAHYDRO-3A,7A-DIH  
YDROXY-1H-BENZIMIDAZOL-2-YL)-L-ORNITHINE)-30B-L-THREONINE-,  
30B-(1,1-DIMETHYLETHYL) ESTER/CN

E204 1 INSULIN (CATTLE), 22B-(N5-(AMINOCARBONYL)-L-ORNITHINE)-26B-D  
E-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LY  
SINE-30B-DE-L-ALANINE-/CN

E205 1 INSULIN (CATTLE), 22B-DE-L-ARGININE-23B-DEGLYCINE-24B-DE-L-P  
HENYLALANINE-25B-DE-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE  
-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANI  
NE-/CN

E206 1 INSULIN (CATTLE), 22B-DE-L-ARGININE-23B-DEGLYCINE-24B-DE-L-P  
HENYLALANINE-25B-DE-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE  
-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANI  
NE-, 4A,13B,17A,21A,/CN

E207 1 INSULIN (CATTLE), 22B-GLYCINE-26B-DE-L-TYROSINE-27B-DE-L-THR  
EONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E208 1 INSULIN (CATTLE), 22B-L-ALANINE-24B-DE-L-PHENYLALANINE-25B-D  
E-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-D  
E-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E209 1 INSULIN (CATTLE), 22B-L-ALANINE-25B-DE-L-PHENYLALANINE-26B-D  
E-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LY  
SINE-30B-DE-L-ALANINE-/CN

=> e

E210 1 INSULIN (CATTLE), 22B-L-ALANINE-26B-DE-L-TYROSINE-27B-DE-L-T  
HREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E211 1 INSULIN (CATTLE), 22B-L-ALANINE-27B-DE-L-THREONINE-28B-DE-L  
PROLINE-29B-DE-L-LYSINE-/CN

E212 1 INSULIN (CATTLE), 22B-L-ALANINE-27B-DE-L-THREONINE-28B-DE-L  
PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E213 1 INSULIN (CATTLE), 22B-L-LYSINE-24B-DE-L-PHENYLALANINE-25B-DE  
-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-DE  
-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E214 1 INSULIN (CATTLE), 22B-L-LYSINE-25B-DE-L-PHENYLALANINE-26B-DE  
-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYS  
INE-30B-DE-L-ALANINE-/CN

E215 1 INSULIN (CATTLE), 22B-L-LYSINE-26B-DE-L-TYROSINE-27B-DE-L-TH

REONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/C  
N

E216 1 INSULIN (CATTLE), 22B-L-LYSINE-27B-DE-L-THREONINE-28B-DE-L-P  
ROLINE-29B-DE-L-LYSINE-/CN

E217 1 INSULIN (CATTLE), 22B-L-LYSINE-27B-DE-L-THREONINE-28B-DE-L-P  
ROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E218 1 INSULIN (CATTLE), 22B-L-ORNITHINE-26B-DE-L-TYROSINE-27B-DE-L  
-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE  
-/CN

E219 1 INSULIN (CATTLE), 23B-D-ALANINE-24B-D-PHENYLALANINE-27B-DE-L  
-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE  
-/CN

E220 1 INSULIN (CATTLE), 23B-D-ALANINE-25B-DE-L-PHENYLALANINE-26B-D  
E-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LY  
SINE-30B-DE-L-ALANINE-/CN

E221 1 INSULIN (CATTLE), 23B-D-ALANINE-25B-DE-L-PHENYLALANINE-26B-D  
E-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LY  
SINE-30B-DE-L-ALANINE-, 24B-METHYL ESTER/CN

=> e

E222 1 INSULIN (CATTLE), 23B-D-ALANINE-27B-DE-L-THREONINE-28B-DE-L-  
PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E223 1 INSULIN (CATTLE), 23B-DEGLYCINE-24B-DE-L-PHENYLALANINE-25B-D  
E-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-D  
E-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E224 1 INSULIN (CATTLE), 23B-DEGLYCINE-24B-DE-L-PHENYLALANINE-25B-D  
E-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-D  
E-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-, 21B-METHYL ES  
TER/CN

E225 1 INSULIN (CATTLE), 23B-L-ALANINE-24B-D-PHENYLALANINE-27B-DE-L  
-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE  
-/CN

E226 1 INSULIN (CATTLE), 23B-L-ALANINE-27B-DE-L-THREONINE-28B-DE-L-  
PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E227 1 INSULIN (CATTLE), 24B-DE-L-PHENYLALANINE-25B-DE-L-PHENYLALAN  
INE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29  
B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E228 1 INSULIN (CATTLE), 24B-L-ALANINE-30B-L-THREONINE-/CN

E229 1 INSULIN (CATTLE), 25B-DE-L-PHENYLALANINE-26B-DE-L-TYROSINE-2  
7B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-  
ALANINE-/CN

E230 1 INSULIN (CATTLE), 25B-L-ALANINE-30B-L-THREONINE-/CN

E231 1 INSULIN (CATTLE), 25B-L-TYROSINE-/CN

E232 1 INSULIN (CATTLE), 26B-(3-(IODO-125I)-L-TYROSINE)-29B-(N6-(4-  
AZIDOBENZOYL)-L-LYSINE)-/CN

E233 1 INSULIN (CATTLE), 26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-D  
E-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

=> e

E234 1 INSULIN (CATTLE), 26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-D  
E-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-, 25B-METHYL ES  
TER/CN

E235 1 INSULIN (CATTLE), 26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-D  
E-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-, 4A,13B,17A,21  
A,21B-PENTAMETHYL ESTER/CN

E236 1 INSULIN (CATTLE), 26B-L-.ALPHA.-GLUTAMINE-27B-DE-L-THREONINE  
-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E237 1 INSULIN (CATTLE), 26B-L-ALANINE-30B-L-THREONINE-/CN

E238 1 INSULIN (CATTLE), 26B-L-PHENYLALANINE-/CN

E239 1 INSULIN (CATTLE), 26B-L-THREONINAMIDE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E240 1 INSULIN (CATTLE), 26B-L-TYROSINAMIDE-27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E241 1 INSULIN (CATTLE), 27B-DE-L-THREONINE-28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E242 1 INSULIN (CATTLE), 27B-L-GLUTAMIC ACID-/CN

E243 1 INSULIN (CATTLE), 28B-DE-L-PROLINE-29B-DE-L-LYSINE-30B-DE-L-ALANINE-/CN

E244 1 INSULIN (CATTLE), 28B-L-ASPARTIC ACID-30B-L-THREONINE-/CN

E245 1 INSULIN (CATTLE), 28B-L-ASPARTIC ACID-30B-L-THREONINE-, 30B-METHYL ESTER/CN

=> e

E246 1 INSULIN (CATTLE), 29B,29B'-(1,12-DIOXO-1,12-DODECANEDIYL)BIS-/CN

E247 1 INSULIN (CATTLE), 29B,29B'-(1,2-DIOXO-1,2-ETHANEDIYL)BIS-/CN

E248 1 INSULIN (CATTLE), 29B,29B'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS(1A-D-ALANINE-1B-D-ALANINE-/CN

E249 1 INSULIN (CATTLE), 29B,29B'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS(1B-DE-L-PHENYLALANINE-2B-(N-((4-AZIDOPHENYL)ACETYL)-L-VALINE)-/CN

E250 1 INSULIN (CATTLE), 29B,29B'-(1,8-DIOXO-1,8-OCTANEDIYL)BIS-/CN

E251 1 INSULIN (CATTLE), 29B-(N6-((2-SULFO-9H-FLUOREN-9-YL)METHOXY)CARBONYL)-L-LYSINE)-/CN

E252 1 INSULIN (CATTLE), 29B-(N6-((1,1-DIMETHYLETHOXY)CARBONYL)-L-LYSINE)-/CN

E253 1 INSULIN (CATTLE), 29B-(N6-((3-FORMYL-2,2-DIMETHYL-4-THIAZOLIDINYLCARBONYL)-L-LYSINE)-, (R)-/CN

E254 1 INSULIN (CATTLE), 29B-(N6-((4-AZIDO-2-NITROPHENYL)ACETYL)-L-LYSINE)-/CN

E255 1 INSULIN (CATTLE), 29B-(N6-((4-AZIDOPHENYL)ACETYL)-L-LYSINE)-/CN

E256 1 INSULIN (CATTLE), 29B-(N6-((9H-FLUOREN-9-YLMETHOXY)CARBONYL)-L-LYSINE)-/CN

E257 1 INSULIN (CATTLE), 29B-(N6-(1-OXOHEDAECYL)-L-LYSINE)-/CN

=> e

E258 1 INSULIN (CATTLE), 29B-(N6-(1-OXOHEXYL)-L-LYSINE)-/CN

E259 1 INSULIN (CATTLE), 29B-(N6-(3-CARBOXY-1-OXOPROPYL)-L-LYSINE)-/CN

E260 1 INSULIN (CATTLE), 29B-(N6-(4-AZIDO-2-NITROPHENYL)-L-LYSINE)-/CN

E261 1 INSULIN (CATTLE), 29B-(N6-(4-AZIDOBENZOYL)-L-LYSINE)-/CN

E262 1 INSULIN (CATTLE), 29B-(N6-(5-(HEXAHYDRO-2-OXO-1H-THIENO(3,4-D)IMIDAZOL-4-YL)-1-OXOPENTYL)-L-LYSINE)-, (3AS-(3A.ALPHA.,4.BETA.,6A.ALPHA.))-/CN

E263 1 INSULIN (CATTLE), 29B-(N6-(7-CARBOXY-1-OXOHEPTYL)-L-LYSINE)-, (29B.FWDARW.1B')-AMIDE WITH 23B-DEGLYCINE-24B-DE-L-PHENYLALANINE-25B-DE-L-PHENYLALANINE-26B-DE-L-TYROSINE-27B-DE-L-THREONINE-28B-DE-L-PROL/CN

E264 1 INSULIN (CATTLE), 29B-(N6-(N-((PHENYLMETHOXY)CARBONYL)-L-.GAMMA.-GLUTAMYL)-L-LYSINE)-, (29B.FWDARW.1A)-LACTAM/CN

E265 1 INSULIN (CATTLE), 29B-(N6-(N-(4-AZIDO-2-NITROPHENYL)GLYCYL)-L-LYSINE)-/CN

E266 1 INSULIN (CATTLE), 29B-(N6-(N-(BROMOACETYL)-.BETA.-.ALANYL)-L-LYSINE)-/CN

E267 1 INSULIN (CATTLE), 29B-(N6-(TRIFLUOROACETYL)-L-LYSINE)-/CN

E268 1 INSULIN (CATTLE), 29B-(N6-ACETYL-L-LYSINE)-/CN

E269 1 INSULIN (CATTLE), 29B-(N6-L-ALANYL-L-LYSINE)-/CN

=> e insulin (human)/cn

E270 1 INSULIN (HUMAN PSYA/BA-CHAIN REDUCED)/CN

E271 1 INSULIN (HUMAN SYNTHETIC CLONE PPGK/PSCI 57-AMINO-ACID FRAGM ENT) /CN

E272 1 --> INSULIN (HUMAN)/CN

E273 1 INSULIN (HUMAN), 10A-L-VALINE-/CN

E274 1 INSULIN (HUMAN), 10B-L-ALANINE-/CN

E275 1 INSULIN (HUMAN), 10B-L-ARGININE-/CN

E276 1 INSULIN (HUMAN), 10B-L-ASPARAGINE-/CN

E277 1 INSULIN (HUMAN), 10B-L-ASPARTIC ACID-/CN

E278 1 INSULIN (HUMAN), 10B-L-ASPARTIC ACID-21A-GLYCINE-28B-L-LYSIN E-29B-L-PROLINE-/CN

E279 1 INSULIN (HUMAN), 10B-L-ASPARTIC ACID-21A-L-ALANINE-28B-L-LYS INE-29B-L-PROLINE-/CN

E280 1 INSULIN (HUMAN), 10B-L-ASPARTIC ACID-24B-D-PHENYLALANINE-28B -L-LYSINE-29B-L-PROLINE-/CN

E281 1 INSULIN (HUMAN), 10B-L-ASPARTIC ACID-24B-GLYCINE-28B-L-LYSIN E-29B-L-PROLINE-/CN

=> s e272,e32,e96

1 "INSULIN (HUMAN)"/CN

1 INSULIN/CN

1 "INSULIN (CATTLE)"/CN

L33 3 ("INSULIN (HUMAN)"/CN OR INSULIN/CN OR "INSULIN (CATTLE)"/CN)

=> d scan

L33 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Insulin (human) (9CI)

SQL 51,30,21

MF C257 H383 N65 O77 S6

CI COM, MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L33 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Insulin (cattle) (9CI)

SQL 51,30,21

MF C254 H377 N65 O75 S6

CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L33 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Insulin (9CI)

MF Unspecified

CI PMS, COM, MAN

09/719, 423

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> d rn 1-3

L33 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS  
RN 11070-73-8 REGISTRY

L33 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS  
RN 11061-68-0 REGISTRY

L33 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS  
RN 9004-10-8 REGISTRY

=> select rn 133 1-3  
E282 THROUGH E284 ASSIGNED

=> s e282-284/crn  
5 11061-68-0/CRN  
0 11070-73-8/CRN  
26 9004-10-8/CRN  
L34 31 (11061-68-0/CRN OR 11070-73-8/CRN OR 9004-10-8/CRN)

=> d scan

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Glucagon, mixt. with epidermal growth factor and insulin (9CI)  
MF Unspecified . Unspecified . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 3

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin (human), polymer with 4-(4-imino-2,5-cyclohexadien-1-ylidene)-2,5-  
cyclohexadien-1-imine (9CI)  
MF (C257 H383 N65 O77 S6 . C12 H10 N2)x  
CI PMS

CM 1

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, compd. with 1-amino-4-[[4-[[4-chloro-6-[[3(or  
 4)-sulfophenyl]amino]-1,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10-  
 dihydro-9,10-dioxo-2-anthracenesulfonic acid (9CI)  
 MF C29 H20 Cl N7 O11 S3 . x Unspecified


CM 1

PAGE 1-A



D1 SO3H

PAGE 2-A



CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=&gt; d his

(FILE 'HOME' ENTERED AT 13:09:05 ON 07 MAR 2003)

FILE 'HCAPLUS' ENTERED AT 13:09:24 ON 07 MAR 2003

L1 71 S WAGENBLAST G?/AU  
 L2 41 S SUTORIS H?/AU  
 L3 36 S SCHLIEPHAKE V?/AU  
 L4 1485 S SCHROEDER J?/AU  
 L5 1738 S KELLER H?/AU  
 L6 30 S JAWOREK T?/AU  
 L7 3348 S L1-6  
 L8 16 S L7 AND FREE RADICAL  
 L9 42391 S N-OXYL? OR N-OXIDE OR 1-OXIDE  
 L10 376085 S PHENOL? OR CRESOL?  
 L11 0 S BIRTHR  
 L12 6 S L8 AND L9-11  
 L13 4 S L12 AND POLYMER?  
 .SELECT RN L13 1-4

FILE 'REGISTRY' ENTERED AT 13:14:11 ON 07 MAR 2003

L14 25 S E1-25

FILE 'HCAPLUS' ENTERED AT 13:14:17 ON 07 MAR 2003

L15 4 S L13 AND L14

FILE 'STNGUIDE' ENTERED AT 13:15:27 ON 07 MAR 2003

FILE 'HCAPLUS' ENTERED AT 13:17:02 ON 07 MAR 2003  
 L16 16833 S ?ORTHOPHOSPH?  
 L17 12 S L16 AND L7  
 L18 0 S L17 AND L10  
 L19 0 S L17 AND POLYMER?  
 L20 1 S L17 AND PURIFICATION/TI  
 L21 0 S L17 AND ALUMINUM/TI  
 L22 0 S L17 AND ALUMIN/TI  
 L23 4 S L17 AND ALUMIUM  
 L24 12 S L17 AND ?PHOSPH?  
 L25 40045 S BIRT?  
 L26 0 S L25 AND L17  
 L27 1070 S L25 AND COMPOUND  
 L28 49 S L25(5A)COMPOUND  
 L29 6 S L28 NOT BIRTH  
 L30 1 S US6458956/PN  
 .SELECT RN L30 1

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 07 MAR 2003

L31 4 S E26-29

FILE 'HCAPLUS' ENTERED AT 13:41:16 ON 07 MAR 2003

L32 1 S L30 AND L31

09/719,423

FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003

E INSULIN/CN  
E INSULIN (HUMAN)/CN

L33 3 S E272,E32,E96  
SELECT RN L33 1-3  
L34 31 S E282-284/CRN

=> d scan


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, mixt. with L-tryptophan (9CI)  
MF C11 H12 N2 O2 . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, mixt. with rapamycin (9CI)  
MF C51 H79 N O13 . Unspecified  
CI MXS

CM 1

Absolute stereochemistry.  
Double bond geometry as shown.



Me

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin (human), polymer with 4-(4-imino-2,5-cyclohexadien-1-ylidene)-2,5-cyclohexadien-1-imine (9CI)  
 MF (C257 H383 N65 O77 S6 . C12 H10 N2)x  
 CI PMS

CM 1

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, mixt. with insulin protamine zinc (9CI)  
 MF Unspecified . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, mixt. with 1-ethenyl-2-pyrrolidinone homopolymer (9CI)  
 MF (C6 H9 N O)x . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CM 3



L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN D-Glucose, mixt. with insulin and potassium chloride (KCl) (9CI)  
 MF C6 H12 O6 . Cl K . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 2

Cl-K

Cl-K

CM 3


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, mixt. with 5-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (9CI)  
 MF C24 H27 N O5 S . Unspecified  
 CI MXS

CM 1



CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin (human), 30Ba-L-arginine-, mixt. with insulin (human) (9CI)  
 MF C263 H395 N69 O78 S6 . C257 H383 N65 O77 S6  
 CI MXS

CM 1

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

09/719, 423

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN D-Glucose, mixt. with 2-hydroxypropanoic acid and insulin (9CI)  
MF C6 H12 O6 . C3 H6 O3 . Unspecified  
CI MXS

CM 1


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

Absolute stereochemistry.



CM 3




L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, compd. with 4,8-dihydroxy-2-quinolincarboxylic acid (9CI)  
MF C10 H7 N O4 . x Unspecified

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

09/719, 423


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, compd. with 2-propenoic acid homopolymer (9CI)  
MF (C<sub>3</sub> H<sub>4</sub> O<sub>2</sub>)<sub>x</sub> . Unspecified

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CM 3




L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, compd. with 1-amino-4-[[4-[[4-chloro-6-[[3(or  
4)-sulfophenyl]amino]-1,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10-  
dihydro-9,10-dioxo-2-anthracenesulfonic acid (9CI)  
MF C<sub>29</sub> H<sub>20</sub> Cl N<sub>7</sub> O<sub>11</sub> S<sub>3</sub> . x Unspecified

CM 1

PAGE 1-A



D1-SO<sub>3</sub>H



CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin (human), 30Ba-L-arginine-30Bb-L-arginine-, mixt. with insulin  
 (human) (9CI)  
 MF C269 H407 N73 O79 S6 . C257 H383 N65 O77 S6  
 CI MXS

CM 1

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, mixt. with N,N-diethylethanamine hydrochloride and sodium dodecyl  
 sulfate (9CI)  
 MF C12 H26 O4 S . C6 H15 N . Cl H . Na . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2



● HCl

CM 3



● Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN D-Glucose, monopotassium salt, mixt. with insulin (9CI)  
 MF C6 H12 O6 . K . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

Absolute stereochemistry.




L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, compd. with 2-methyl-2-propenoic acid homopolymer (9CI)  
 MF (C4 H6 O2)x . Unspecified

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CM 3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN .beta.-Cyclodextrin, compd. with insulin (9CI)  
 MF C42 H70 O35 . x Unspecified


CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



09/719, 423

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-.beta.-L-  
arabinopyranosyl-(1.fwdarw.6)-O-[2,6-diamino-2,3,4,6-tetrahydroxy-.alpha.-D-  
erythro-hexopyranosyl-(1.fwdarw.4)]-2-deoxy-, sulfate (salt), mixt. with  
insulin (9CI)  
MF C19 H39 N5 O7 . x H2 O4 S . Unspecified  
CI MXS


CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 2

CM 3

Absolute stereochemistry.



CM 4



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin zinc, mixt. with insulin (9CI)  
MF Unspecified . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS


09/719,423

IN Insulin, compd. with 2,4,6-trinitrophenol (9CI)  
MF C6 H3 N3 O7 . x Unspecified

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, compd. with magnesium aluminosilicate (9CI)  
MF Unspecified . x Unspecified

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin (human), mixt. with 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide (9CI)  
MF C257 H383 N65 O77 S6 . C23 H28 Cl N3 O5 S  
CI MXS

CM 1

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2



09/719, 423

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, mixt. with pancreatic basic trypsin inhibitor (9CI)  
MF Unspecified . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, mixt. with heparin (9CI)  
MF Unspecified . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Glucagon, mixt. with epidermal growth factor and insulin (9CI)  
MF Unspecified . Unspecified . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 3

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin, mixt. with proinsulin (9CI)  
MF Unspecified . Unspecified  
CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin (human), mixt. with insulin protamine zinc (9CI)  
 MF C257 H383 N65 O77 S6 . Unspecified  
 CI MXS

CM 1

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Calcitonin, mixt. with insulin (9CI)  
 MF Unspecified . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 2


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Insulin, mixt. with aspartic acid monopotassium salt, D-glucose and  
 potassium hydrogen (T-4)-bis[aspartato(2-)-.kappa.N,.kappa.O1]magnesate(2-  
 ) (9CI)  
 MF C8 H10 Mg N2 O8 . C6 H12 O6 . C4 H7 N O4 . H . 2 K . Unspecified  
 CI MXS

CM 1

● H<sup>+</sup>● K<sup>+</sup>



● H<sup>+</sup>

● K<sup>+</sup>

CM 2

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 3



● K

CM 4

Absolute stereochemistry.




L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Pregn-4-ene-3,20-dione, mixt. with (R\*,S\*)-4,4'-(1,2-diethyl-1,2-ethanediyl)bis[phenol] and insulin (9CI)  
 MF C21 H30 O2 . C18 H22 O2 . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 2

Relative stereochemistry.



CM 3

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L34 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN D-Glucose, mixt. with insulin (9CI)  
 MF C6 H12 O6 . Unspecified  
 CI MXS

CM 1

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

Absolute stereochemistry.



ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 13:09:05 ON 07 MAR 2003)

FILE 'HCAPLUS' ENTERED AT 13:09:24 ON 07 MAR 2003

L1 71 S WAGENBLAST G?/AU  
 L2 41 S SUTORIS H?/AU  
 L3 36 S SCHLIEPHAKE V?/AU  
 L4 1485 S SCHROEDER J?/AU  
 L5 1738 S KELLER H?/AU  
 L6 30 S JAWOREK T?/AU  
 L7 3348 S L1-6  
 L8 16 S L7 AND FREE RADICAL  
 L9 42391 S N-OXYL? OR N-OXIDE OR 1-OXIDE  
 L10 376085 S PHENOL? OR CRESOL?  
 L11 0 S BIRTHER  
 L12 6 S L8 AND L9-11  
 L13 4 S L12 AND POLYMERI?  
 SELECT RN L13 1-4

FILE 'REGISTRY' ENTERED AT 13:14:11 ON 07 MAR 2003

L14 25 S E1-25

FILE 'HCAPLUS' ENTERED AT 13:14:17 ON 07 MAR 2003

L15 4 S L13 AND L14

FILE 'STNGUIDE' ENTERED AT 13:15:27 ON 07 MAR 2003

FILE 'HCAPLUS' ENTERED AT 13:17:02 ON 07 MAR 2003

L16 16833 S PORTHOPHOSPH?  
 L17 12 S L16 AND L7  
 L18 0 S L17 AND L10  
 L19 0 S L17 AND POLYMER?  
 L20 1 S L17 AND PURIFICATION/TI  
 L21 0 S L17 AND ALUMINUM/TI  
 L22 0 S L17 AND ALUMIN/TI  
 L23 4 S L17 AND ALUMINUM  
 L24 12 S L17 AND ?PHOSPH?  
 L25 40045 S BIRT?  
 L26 0 S L25 AND L17  
 L27 1070 S L25 AND COMPOUND  
 L28 49 S L25(5A)COMPOUND  
 L29 6 S L28 NOT BIRTH  
 L30 1 S US6458956/PN  
 SELECT RN L30 1

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 07 MAR 2003

L31 4 S E26-29

FILE 'HCAPLUS' ENTERED AT 13:41:16 ON 07 MAR 2003

L32 1 S L30 AND L31

FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003

L33 E INSULIN/CN  
 E INSULIN (HUMAN)/CN  
 3 S E272,E32,E96  
 SELECT RN L33 1-3  
 L34 31 S E282-284/CRN

=> d

L34 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 487021-90-9 REGISTRY  
CN Insulin (human), mixt. with insulin protamine zinc (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Mixtard 30/70 Penset  
MF C257 H383 N65 O77 S6 . Unspecified  
CI MXS  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 11061-68-0  
CMF C257 H383 N65 O77 S6  
CCI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 9004-17-5  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s "insulin"  
L35 6509 "INSULIN"

=> s 135 and rt3/nte  
0 RT3/NTE  
L36 0 L35 AND RT3/NTE

=> s 135 and "rt3"  
18 "RT3"  
L37 0 L35 AND "RT3"

=> s 135 and nte/fs  
0 NTE/FS  
L38 0 L35 AND NTE/FS

=> s 135 and nte/fa  
11739044 NTE/FA  
L39 4027 L35 AND NTE/FA

=> s 139 and "rt3"  
18 "RT3"  
L40 0 L39 AND "RT3"

=> s "rt3"  
L41 18 "RT3"

09/719, 423

=> d scan

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN DNA (**Thermococcus strain Rt3 gene amy plus flanks**) (9CI)  
SQL 2372  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN **Extensin (pea clone PsEXT.RT3 root nodule)** (9CI)  
SQL 144  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN DNA (**human immunodeficiency virus 1 clone RT3.12p gene env 646-nucleotide fragment**) (9CI)  
SQL 646  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN **Amylase, .alpha.- (Thermococcus sp. Rt3 gene amy)** (9CI)  
SQL 469  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN DNA (**rat clone RT3-1B tRNALeu gene**) (9CI)  
SQL 83  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (*Arabidopsis thaliana* mitochondria clone 39e8 *Ty1/copia-like*  
     element gene RT3) (9CI)  
 SQL 349  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (*pea* clone *PsEXT.RT3* root nodule extensin cDNA plus flanks)  
     (9CI)  
 SQL 462  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (*human immunodeficiency virus 1* clone RT3.11p gene env  
     631-nucleotide fragment) (9CI)  
 SQL 631  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (*Rattus tanezumi* clone ERV-L Rat Rt3 endogenous retroviral-like  
     element gene pol fragment) (9CI)  
 SQL 327  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (*rat* clone RT3-1B tRNAGly gene) (9CI)  
 SQL 72  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (*human immunodeficiency virus 1* clone RT3.6p gene env  
     661-nucleotide fragment) (9CI)  
 SQL 661  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Envelope protein (human immunodeficiency virus type 1 isolate RT3  
 gene env V4/V5 hypervariable region fragment) (9CI)  
 SQL 83  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (human immunodeficiency virus 1 clone RT3.10p gene env  
 599-nucleotide fragment) (9CI)  
 SQL 599  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN DNA (Thermococcus strain Rt3 16S rRNA gene) (9CI)  
 SQL 1457  
 MF Unspecified  
 CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L41 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo- (9CI)  
 MF C15 H12 I3 N O4  
 CI COM

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s 141 and C15 H12 I3 N O4/mf  
 50 C15 H12 I3 N O4/MF  
 L42 1 L41 AND C15 H12 I3 N O4/MF

=> d

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
 RN 5817-39-0 REGISTRY  
 CN L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Alanine, 3-[4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl]-, L- (8CI)  
 OTHER NAMES:  
 CN 3',5',3-Triiodothyronine  
 CN 3,3',5'-L-Triiodothyronine  
 CN 3,3',5'-T3  
 CN 3,3',5'-Triodo-L-thyronine  
 CN 3,3',5'-Triiodothyronine  
 CN Isoliothyronine  
 CN Reverse L-triiodothyronine  
 CN Reverse T3  
 CN Reverse triiodothyronine  
 CN rT3  
 FS STEREOSEARCH  
 DR 2820-50-0  
 MF C15 H12 I3 N O4  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM,  
 DDFU, DRUGU, EMBASE, IPA, MEDLINE, PROMT, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1504 REFERENCES IN FILE CA (1962 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1505 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file caplus

09/719,423

FILE 'CAPLUS' ENTERED AT 15:07:36 ON 07 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2003 VOL 138 ISS 11  
FILE LAST UPDATED: 6 Mar 2003 (20030306/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 142
L43      1514 L42

=> s 143(L)(rrt or rct)/rl
      0 RRT/RL
      2498896 RCT/RL
L44      82 L43(L)(RRT OR RCT)/RL

=> s 144 and insulin
      148504 INSULIN
      1884 INSULINS
      148539 INSULIN
      ((INSULIN OR INSULINS))
L45      0 L44 AND INSULIN

=> s 143 and insulin/it
      101660 INSULIN/IT
      799 INSULINS/IT
      101705 INSULIN/IT
      ((INSULIN OR INSULINS)/IT)
L46      35 L43 AND INSULIN/IT

=> s 146 and conjug?
      181685 CONJUG?
L47      2 L46 AND CONJUG?

=> d ti 1-2

L47  ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
TI  Method for assaying biomolecules and other constituents using indicator
conjugates with synthetic nucleounits in lateral flow, liquid, and
dry chemistry techniques

L47  ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
TI  Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects
of glucose, glucagon, and insulin
```

=> d scan

L47 2 ANSWERS CAPLUS COPYRIGHT 2003 ACS  
 CC 2-2 (Hormone Pharmacology)  
 Section cross-reference(s): 13  
 TI Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects  
 of glucose, glucagon, and insulin  
 ST hepatocyte thyroxine metab insulin glucagon; triiodothyronine metab  
 hepatocyte; reverse triiodothyronine metab hepatocyte  
 IT Thyroid hormones  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (metab. of, by hepatocyte, glucagon and glucose and **insulin**  
 effect on)  
 IT Liver, metabolism  
 (hepatocyte, thyroid hormones metab. by, glucagon and glucose and  
**insulin** effect on)  
 IT 51-52-5  
 RL: BIOL (Biological study)  
 (deiodinases of hepatocyte response to, thyroid hormone metab. in  
 relation to)  
 IT 5817-39-0 6893-02-3  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (metab. of, by hepatocyte, concn. effect on)  
 IT 51-48-9, biological studies  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (metab. of, by hepatocyte, glucagon and glucose and **insulin**  
 effect on)  
 IT 70712-46-8 74506-30-2  
 RL: BIOL (Biological study)  
 (of hepatocyte, propylthiouracil effect on)  
 IT 50-99-7, biological studies  
 RL: BIOL (Biological study)  
 (thyroid hormone metab. by hepatocytes in relation to)  
 IT 9004-10-8, biological studies  
 RL: BIOL (Biological study)  
 (thyroxine deiodination by hepatocyte stimulation by, glucagon  
 inhibition of)  
 IT 9007-92-5, biological studies  
 RL: BIOL (Biological study)  
 (thyroxine deiodination stimulation by **insulin** inhibition by,  
 in hepatocyte)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L47 2 ANSWERS CAPLUS COPYRIGHT 2003 ACS  
 IC ICM C12Q001-68  
 NCL 435006000  
 CC 9-16 (Biochemical Methods)  
 TI Method for assaying biomolecules and other constituents using indicator  
**conjugates** with synthetic nucleounits in lateral flow, liquid, and  
 dry chemistry techniques  
 ST dipstick lateral flow device oligonucleotide aptamer biomol drug detection  
 IT Corticosteroids, analysis  
 RL: ANT (Analyte); ANST (Analytical study)

(17-hydroxy; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Steroids, analysis  
 RL: ANT (Analyte); ANST (Analytical study)  
 (17-ketogenic; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Proteins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (C-reactive; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (EBNA (Epstein-Barr virus-assocd. nuclear antigen), IgG binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (Epstein-Barr early; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Immunoglobulins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (G, anti-peroxidase; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Cytomegalovirus  
 Mycoplasma  
 Rubella  
 Toxoplasma  
 (IgG and IgM binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Helicobacter pylori  
 Human herpesvirus 1  
 Human herpesvirus 2  
 (IgG binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Legionella  
 (IgG, IgM, and IgA binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (VCA (viral capsid antigen), IgG and IgM binding to Epstein-Barr; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Entamoeba histolytica  
 (amebiasis; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Proteins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (amyloid-assocd.; method for assaying biomols. and other constituents

using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Neutrophil  
 (antibodies binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Cardiolipins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (antibodies binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (antinuclear; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Jo-1; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, SS-A/Ro; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, SS-B/La; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Scl-70; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Sm (Smith antigen); method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Sm/RNP; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (cancer antigen 125; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Hemoglobins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (carboxyhemoglobins; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Latex  
 (colored particles of, **conjugates**; method for assaying biomols. and other constituents using indicator **conjugates**)

with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Metals, biological studies  
 Plastics, biological studies  
 Rubber, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (colored particles of, **conjugates**; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Complement  
 RL: ANT (Analyte); ANST (Analytical study)  
 (components of; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT DNA  
 RL: ANT (Analyte); ANST (Analytical study)  
 (double-stranded, antibodies binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (extractable nuclear; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Fats and Glyceridic oils, analysis  
 RL: ANT (Analyte); ANST (Analytical study)  
 (fecal; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Proteins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (fetoproteins; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (galactosaminidase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (glucosaminidase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Lipoproteins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (high-d.; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (hydroxybenzoate hydroxylase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Enzymes, biological studies  
RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(maltosidase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Angiogenesis  
Blood  
Blood analysis  
Human herpesvirus 3  
Human immunodeficiency virus  
Leukocyte  
Urine analysis  
(method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Albumins, analysis  
Alcohols, analysis  
Antibodies  
Apolipoproteins  
Bile acids  
Cannabinoids  
Carotenes, analysis  
Catecholamines, analysis  
Estrogens  
Fatty acids, analysis  
Ferritins  
Fibrinogens  
Gastric acid  
Glycerides, analysis  
Gonadotropins  
Haptoglobin  
Hemoglobins  
Hemoglobins, methemoglobins  
Hemopexins  
Immunoglobulins  
Ketone bodies  
Lecithins  
Lipoproteins  
Melanins  
Mucopolysaccharides, analysis  
Myelin basic protein  
Myoglobins  
Opioids  
Pentoses  
Phenols, analysis  
Phospholipids, analysis  
Prostaglandins  
Prostate-specific antigen  
Rheumatoid factors  
Thyroglobulin  
Transcortins  
Transferrins  
Transthyretin  
Vitamins  
.alpha.1-Acid glycoprotein  
RL: ANT (Analyte); ANST (Analytical study)  
(method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq.,

and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (microsomal; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Aptamers  
 (oligonucleotide; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Antibodies  
 RL: ANT (Analyte); ANST (Analytical study)  
 (thyroid; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Globulins, analysis  
 RL: ANT (Analyte); ANST (Analytical study)  
 (thyroxine-binding; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT Pigments, biological  
 (urobilinogens; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 128028-50-2, Proteinase-3  
 RL: ANT (Analyte); ANST (Analytical study)  
 (IgG binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 50-36-2, Cocaine  
 RL: ANT (Analyte); ANST (Analytical study)  
 (and metabolites; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 144-62-7, Ethanedioic acid, analysis  
 RL: ANT (Analyte); ANST (Analytical study)  
 (buffer/analyte; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 50-21-5, analysis  
 RL: ANT (Analyte); ARU (Analytical role, unclassified); ANST (Analytical study)  
 (buffer/analyte; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 77-86-1, TRIS 77-92-9, Citric acid, analysis 102-71-6,  
 Triethanolamine, analysis 103-47-9, CHES 110-15-6, Succinic acid,  
 analysis 150-25-4, BICINE 463-79-6, Carbonic acid, analysis  
 497-19-8, Sodium carbonate, analysis 868-14-4, Potassium hydrogen  
 tartrate 877-24-7, Potassium hydrogen phthalate 1132-61-2, MOPS  
 1135-40-6, CAPS 1303-96-4, Borax 1330-43-4, Sodium tetraborate  
 4432-31-9, MES 5625-37-6, PIPES 5704-04-1, TRICINE 6976-37-0,  
 BIS-TRIS 7365-44-8, TES 7365-45-9, HEPES 7365-82-4, ACES  
 7601-89-0, Sodium perchlorate 7601-90-3, Perchloric acid, analysis  
 7664-38-2, Phosphoric acid, analysis 7664-93-9, Sulfuric acid, analysis  
 7697-37-2, Nitric acid, analysis 7775-09-9, Sodium chlorate  
 10043-35-3, Boric acid, analysis 10191-18-1, BES 10196-30-2,  
 2-Amino-2-ethyl-1-propanol 13530-68-2, Chromic acid 16052-06-5, EPPS  
 26239-55-4, ADA 29915-38-6, N-Tris[Hydroxymethyl]methyl-3-

aminopropanesulfonic acid 64431-96-5, BIS-TRIS PROPANE 68189-43-5,  
 POPSO 68399-77-9, MOPSO 68399-78-0, HEPPSO 68399-79-1, AMPSO  
 68399-80-4, DIPSO 68399-81-5, TAPSO 73463-39-5, CAPSO 109191-31-3,  
 N-[2-Acetamido]-2-aminoethanesulfonic acid)  
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
 (buffer; method for assaying biomols. and other constituents using  
 indicator **conjugates** with synthetic nucleounits in lateral  
 flow, liq., and dry chem. techniques)

IT 9001-60-9, Lactate dehydrogenase 9001-78-9, Alkaline phosphatase  
 9002-12-4, Uricase  
 RL: ANT (Analyte); ANST (Analytical study)  
 (indicator/analyte; method for assaying biomols. and other constituents  
 using indicator **conjugates** with synthetic nucleounits in  
 lateral flow, liq., and dry chem. techniques)

IT 53-59-8, NADP 53-84-9, Nicotinamide adenine dinucleotide 63-42-3  
 69-79-4 83-07-8, 4-Aminoantipyrine 87-66-1, Pyrogallol 91-67-8,  
 N,N-Diethyl-m-toluidine 91-95-2, 3,3'-Diaminobenzidine 108-95-2,  
 Phenol, biological studies 119-90-4 120-83-2, 2,4-Dichlorophenol  
 121-69-7, Dimethylaniline, biological studies 132-32-1, 3-Amino-9-ethyl  
 carbazole 298-83-9, Nitro Blue Tetrazolium 369-07-3,  
 2-Nitrophenyl-.beta.-D-galactopyranoside 1094-61-7, Nicotinamide  
 mononucleotide 1128-67-2, 3-Methyl-2-benzothiazolinonehydrazone  
 1851-07-6, Nicotinamide hypoxanthine dinucleotide 2280-44-6,  
 Glucopyranose 2438-80-4 3025-88-5, 2-5, Dimethyl-2,5-  
 dihydroperoxyhexane 3150-24-1 3416-24-8, Glucosamine 5094-33-7,  
 4-Aminophenyl-.beta.-D-galactopyranoside 6160-80-1, 4-Methylumbelliferyl-  
 .beta.-D-glucuronide 6556-12-3, Glucuronic acid 6739-64-6,  
 Nicotinamide hypoxanthine dinucleotide phosphate 7240-90-6 7298-93-3,  
 .alpha.-NAD 7535-00-4, Galactosamine 9001-34-7, Galactosidase  
 9001-37-0, Glucose oxidase 9001-40-5, Glucose-6-phosphate dehydrogenase  
 9001-45-0, Glucuronidase 9001-46-1, Glutamate dehydrogenase 9001-55-2,  
 Hydroxybutyrate dehydrogenase 9001-64-3, Malate dehydrogenase  
 9001-65-4, Mannitol dehydrogenase 9001-68-7, NADPH oxidoreductase  
 9002-17-9, Xanthine oxidase 9003-99-0, Peroxidase 9013-05-2,  
 Phosphatase 9013-79-0, Esterase 9016-17-5, Aryl sulfatase 9016-18-6,  
 Carboxyl esterase 9025-35-8, .alpha.-Galactosidase 9026-00-0,  
 Cholesterol esterase 9028-14-2, Glycerol dehydrogenase 9028-53-9,  
 Glucose dehydrogenase 9028-67-5, Choline oxidase 9028-76-6,  
 Cholesterol oxidase 9028-84-6, Formaldehyde dehydrogenase 9029-44-1,  
 Ascorbate oxidase 9031-11-2, .beta.-Lactosidase 9032-92-2, Glycosidase  
 9033-06-1, Glucosidase 9035-73-8, Oxidase 9035-82-9, Dehydrogenase  
 9046-28-0, Glycerophosphate oxidase 9046-59-7, Hydroxylase 9055-15-6,  
 Oxidoreductase 9067-74-7, Arabinosidase 9068-67-1, Sulfatase  
 9073-63-6, Alcohol oxidase 9075-65-4, Glycerol-3-phosphate dehydrogenase  
 9082-71-7, Leucine dehydrogenase 10257-31-5, Xylopyranose 26281-43-6  
 28752-68-3, ABTS 33993-25-8, 2-Naphthyl-.beta.-D-galactopyranoside  
 36473-36-6 36783-03-6, TOPS 37211-66-8, Mannosidase 37329-65-0,  
 .beta.-D-Cellobiosidase 45935-73-7, p-Hydroxybenzene Sulfonate  
 46032-76-2, Mannopyranose 46489-28-5 50443-29-3 51349-63-4  
 51652-08-5 54827-17-7, 3,3',5,5'-Tetramethylbenzidine 56846-39-0  
 56973-46-7 61116-22-1, Acyl-CoA oxidase 72943-20-5 82611-88-9  
 82692-96-4, ADOS 83777-30-4, DAOS 88795-34-0, ADPS 89299-64-9,  
 Arabinopyranose 90836-13-8, ALOS 91395-87-8 93863-88-8 94129-58-5  
 96497-76-6 97753-82-7 99304-66-2, DAPS 99304-67-3, MAPS  
 101764-19-6 102636-89-5, ALPS 110592-38-6 111070-05-4, Fucosidase  
 112046-91-0 113079-84-8 125858-89-1, Xylosidase 126400-78-0,  
 N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline 126787-65-3  
 135622-84-3, Fructose dehydrogenase 138182-21-5 181066-50-2,  
 Bis-MAPS-C 2 207595-15-1 207727-11-5 380637-04-7, MADB 477532-32-4

RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 50-00-0, Formaldehyde, analysis 50-02-2, Dexamethasone 50-06-6, Phenobarbital, analysis 50-22-6, Corticosterone 50-23-7, Cortisol 50-27-1, Estriol 50-28-2, Estradiol, analysis 50-33-9, Phenylbutazone, analysis 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, analysis 50-56-6, Oxytocin, analysis 50-67-9, Serotonin, analysis 50-81-7, Ascorbic acid, analysis 50-99-7, Glucose, analysis 51-06-9, Procainamide 51-35-4, Hydroxyproline 51-48-9, Thyroxine, analysis 52-39-1, Aldosterone 52-90-4, Cysteine, analysis 53-02-1, Tetrahydrocortisol 53-16-7, Estrone, analysis 53-43-0, Dehydroepiandrosterone 54-16-0, 5-Hydroxyindoleacetic acid, analysis 54-36-4, Metyrapone 54-85-3, Isoniazid 55-10-7, Vanillylmandelic acid 56-40-6, Glycine, analysis 56-41-7, Alanine, analysis 56-54-2, Quinidine 56-73-5, Glucose-6-phosphate 56-75-7, Chloramphenicol 56-81-5, Glycerol, analysis 56-85-9, Glutamine, analysis 56-89-3, Cystine, analysis 57-00-1, Creatine 57-12-5, Cyanide, analysis 57-13-6, Urea, analysis 57-27-2, Morphine, analysis 57-41-0, Diphenylhydantoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-48-7, Fructose, analysis 57-50-1, Sucrose, analysis 57-53-4, Meprobamate 57-83-0, Progesterone, analysis 57-88-5, Cholesterol, analysis 58-08-2, Caffeine, analysis 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-55-9, Theophylline, analysis 58-86-6, Xylose, analysis 59-05-2, Methotrexate 59-23-4, Galactose, analysis 59-30-3, analysis 59-67-6, Niacin, analysis 60-18-4, Tyrosine, analysis 60-27-5, Creatinine 60-92-4, Cyclic AMP 61-90-5, Leucine, analysis 62-44-2, Phenacetin 63-05-8, Androstenedione 63-42-3, Lactose 63-68-3, Methionine, analysis 63-91-2, Phenylalanine, analysis 64-17-5, Ethanol, analysis 64-77-7, Tolbutamide 64-85-7, 11-Deoxycorticosterone 67-56-1, Methanol, analysis 68-60-0, Tetrahydrodeoxycortisol 68-96-2, 17-Hydroxyprogesterone 69-72-7D, Salicylic acid, derivs. 69-93-2, Uric acid, analysis 70-18-8, Glutathione, analysis 72-18-4, Valine, analysis 72-44-6, Methaqualone 72-69-5, Nortriptyline 73-32-5, Isoleucine, analysis 76-42-6, Oxycodone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-75-5, Thiopental 76-99-3, Methadone 77-10-1, Phencyclidine 77-21-4, Glutethimide 77-41-8, Methylsuximide 77-67-8, Ethosuximide 79-14-1, Glycolic acid, analysis 79-83-4, Pantothenic acid 81-25-4, Cholic acid 82-58-6, Lysergic acid 83-44-3, Deoxycholic acid 83-88-5, Riboflavin, analysis 86-34-0, Phenoximide 87-86-5, Pentachlorophenol 97-31-4, Normetanephrine 99-66-1, Valproic acid 103-90-2, Acetaminophen 107-21-1, Ethylene glycol, analysis 113-18-8, Ethchlorvynol 123-63-7, Paraldehyde 125-33-7, Primidone 125-64-4, Methylprylon 127-17-3, Pyruvic acid, analysis 137-58-6, Lidocaine 143-74-8, Phenolsulfonphthalein 145-13-1, Pregnenolone 152-58-9, 11-Deoxycortisol 298-46-4, Carbamazepine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-04-5, Thiocyanate, analysis 302-17-0, Chloral hydrate 306-08-1, Homovanillic acid 359-83-1, Pentazocine 438-60-8, Protriptyline 439-14-5, Diazepam 451-13-8, Homogentisic acid 466-99-9, Hydromorphone 469-62-5, Propoxyphene 487-90-1, Porphobilinogen 521-18-6, Dihydrotestosterone 525-66-6, Propranolol 537-46-2, Methamphetamine 553-12-8, Protoporphyrin 555-30-6, Methylldopa 591-81-1, .gamma.-Hydroxybutyric acid 604-75-1, Oxazepam 635-65-4, Bilirubin, analysis 651-48-9, Dehydroepiandrosterone sulfate 846-49-1, Lorazepam 1098-45-9, Pregnanetriol 1319-82-0, Aminocaproic

acid 1330-20-7, Xylene, analysis 1393-25-5, Secretin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam 1668-19-5, Doxepin 3737-09-5, Disopyramide 4205-90-7, Clonidine 4429-04-3, Fructosamine 4685-14-7, Paraquat 4697-36-3, Carbenicillin 5001-33-2, Metanephrite 5817-39-0, Reverse triiodothyronine 6027-13-0, Homocysteine 6893-02-3, Triiodothyronine 7439-89-6, Iron, analysis 7439-92-1, Lead, analysis 7439-93-2, Lithium, analysis 7439-95-4, Magnesium, analysis 7439-97-6, Mercury, analysis 7439-98-7, Molybdenum, analysis 7440-02-0, Nickel, analysis 7440-28-0, Thallium, analysis 7440-47-3, Chromium, analysis 7440-57-5, Gold, analysis 7440-66-6, Zinc, analysis 7440-70-2, Calcium, analysis 7782-49-2, Selenium, analysis 7783-06-4, Hydrogen sulfide, analysis 8063-07-8, Kanamycin 9000-86-6, Alanine aminotransferase 9000-92-4, Amylase 9000-94-6, Antithrombin 9001-08-5, Pseudocholinesterase 9001-10-9, Pepsinogen 9001-15-4, Creatine kinase 9001-58-5, Isocitrate dehydrogenase 9001-62-1, Lipase 9001-63-2, Lysozyme 9001-77-8, Acid phosphatase 9001-80-3, Phosphofructokinase 9001-91-6, Plasminogen 9002-60-2, Adrenocorticotrophic hormone, analysis 9002-61-3, Chorionic gonadotropin 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Growth hormone 9002-76-0, Gastrin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, analysis 9007-12-9, Calcitonin 9007-92-5, Glucagon, analysis 9014-48-6, Transketolase 9015-94-5, Renin, analysis 9024-52-6, Aldolase 9035-54-5, Placental lactogen 9035-68-1, Proinsulin 9035-81-8, Antitrypsin 11000-17-2, Antidiuretic hormone 11016-39-0, Properdin 12794-10-4D, Benzodiazepine, derivs. 14797-65-0, Nitrite, analysis 14838-15-4, Phenylpropanolamine 15687-27-1, Ibuprofen 17617-23-1, Flurazepam 20830-75-5, Digoxin 23887-31-2, Clorazepate 24305-27-9, Thyrotropin-releasing hormone 24959-67-9, Bromide, analysis 26316-36-9, Uroporphyrin 26445-07-8, Pregnanediol 27121-71-7, Coproporphyrin 29679-58-1, Fenoprofen 32795-44-1, n-Acetylprocainamide 32986-56-4, Tobramycin 37221-79-7, Vasoactive intestinal polypeptide 37517-28-5, Amikacin 39335-01-8, Macroamylase 51481-61-9, Cimetidine 54143-55-4, Flecainide 56391-56-1, Netilmicin 59112-80-0, c-Peptide 59763-91-6, Pancreatic polypeptide 59865-13-3, Cyclosporine 67763-96-6, Somatomedin c 69776-17-6 85876-02-4, Glutamyltransferase 152923-57-4, Lutropin

RL: ANT (Analyte); ANST (Analytical study)  
(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 7727-37-9, Nitrogen, analysis

RL: ANT (Analyte); ANST (Analytical study)  
(protein-assocd. and nonprotein; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 13:09:05 ON 07 MAR 2003)

FILE 'HCAPLUS' ENTERED AT 13:09:24 ON 07 MAR 2003

L1	71 S WAGENBLAST G?/AU
L2	41 S SUTORIS H?/AU
L3	36 S SCHLIEPHAKE V?/AU
L4	1485 S SCHROEDER J?/AU

09/719, 423

L5 1738 S KELLER H?/AU  
L6 30 S JAWOREK T?/AU  
L7 3348 S L1-6  
L8 16 S L7 AND FREE RADICAL  
L9 42391 S N-OXYL? OR N-OXIDE OR 1-OXIDE  
L10 376085 S PHENOL? OR CRESOL?  
L11 0 S BIRTHER  
L12 6 S L8 AND L9-11  
L13 4 S L12 AND POLYMERI?  
SELECT RN L13 1-4

FILE 'REGISTRY' ENTERED AT 13:14:11 ON 07 MAR 2003  
L14 25 S E1-25

FILE 'HCAPLUS' ENTERED AT 13:14:17 ON 07 MAR 2003  
L15 4 S L13 AND L14

FILE 'STNGUIDE' ENTERED AT 13:15:27 ON 07 MAR 2003

FILE 'HCAPLUS' ENTERED AT 13:17:02 ON 07 MAR 2003  
L16 16833 S ?ORTHOPHOSPH?  
L17 12 S L16 AND L7  
L18 0 S L17 AND L10  
L19 0 S L17 AND POLYMER?  
L20 1 S L17 AND PURIFICATION/TI  
L21 0 S L17 AND ALUMINUM/TI  
L22 0 S L17 AND ALUMIN/TI  
L23 4 S L17 AND ALUMINUM  
L24 12 S L17 AND ?PHOSPH?  
L25 40045 S BIRT?  
L26 0 S L25 AND L17  
L27 1070 S L25 AND COMPOUND  
L28 49 S L25(5A) COMPOUND  
L29 6 S L28 NOT BIRTH  
L30 1 S US6458956/PN  
SELECT RN L30 1

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 07 MAR 2003  
L31 4 S E26-29

FILE 'HCAPLUS' ENTERED AT 13:41:16 ON 07 MAR 2003  
L32 1 S L30 AND L31

FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003  
E INSULIN/CN  
E INSULIN (HUMAN) /CN  
L33 3 S E272,E32,E96  
SELECT RN L33 1-3  
L34 31 S E282-284/CRN  
L35 6509 S "INSULIN"  
L36 0 S L35 AND RT3/NTE  
L37 0 S L35 AND "RT3"  
L38 0 S L35 AND NTE/FS  
L39 4027 S L35 AND NTE/FA  
L40 0 S L39 AND "RT3"  
L41 18 S "RT3"  
L42 1 S L41 AND C15 H12 I3 N O4/MF

FILE 'CAPLUS' ENTERED AT 15:07:36 ON 07 MAR 2003

L43 1514 S L42  
 L44 82 S L43(L) (RRT OR RCT)/RL  
 L45 0 S L44 AND INSULIN  
 L46 35 S L43 AND INSULIN/IT  
 L47 2 S L46 AND CONJUG?  
  
 => s 143 and insulin  
     148504 INSULIN  
     1884 INSULINS  
     148539 INSULIN  
         (INSULIN OR INSULINS)  
 L48 60 L43 AND INSULIN  
  
 => s 148 and conjugat?  
     180905 CONJUGAT?  
 L49 2 L48 AND CONJUGAT?  
  
 => d ti 1-2  
  
 L49 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS  
 TI Method for assaying biomolecules and other constituents using indicator  
     conjugates with synthetic nucleounits in lateral flow, liquid, and  
     dry chemistry techniques  
  
 L49 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS  
 TI Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects  
     of glucose, glucagon, and **insulin**  
  
 => s 148 and link?  
     352651 LINK?  
 L50 2 L48 AND LINK?  
  
 => d ti 1-2  
  
 L50 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS  
 TI Effects of thyroid hormones on cartilage sulfation in **sex-linked**  
     dwarf chickens  
  
 L50 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS  
 TI Effect of the **sex-linked** dwarf gene on thyrotropic and  
     somatotropic axes in the chick embryo  
  
 => s 148 and covalent?  
     79233 COVALENT?  
 L51 0 L48 AND COVALENT?  
  
 => s 148 and react?  
     4107506 REACT?  
 L52 3 L48 AND REACT?  
  
 => d ti 1-3  
  
 L52 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS  
 TI Method for assaying biomolecules and other constituents using indicator  
     conjugates with synthetic nucleounits in lateral flow, liquid, and dry  
     chemistry techniques

09/719, 423

L52 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS  
TI Endocrine and metabolic responses in children with meningococcal sepsis:  
striking differences between survivors and nonsurvivors

L52 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS  
TI Hormonal control of a low Km (type II) iodothyronine 5'-deiodinase in  
cultured NB41A3 mouse neuroblastoma cells

=> d his

(FILE 'HOME' ENTERED AT 13:09:05 ON 07 MAR 2003)

FILE 'HCAPLUS' ENTERED AT 13:09:24 ON 07 MAR 2003

L1 71 S WAGENBLAST G?/AU  
L2 41 S SUTORIS H?/AU  
L3 36 S SCHLIEPHAKE V?/AU  
L4 1485 S SCHROEDER J?/AU  
L5 1738 S KELLER H?/AU  
L6 30 S JAWOREK T?/AU  
L7 3348 S L1-6  
L8 16 S L7 AND FREE RADICAL  
L9 42391 S N-OXYL? OR N-OXIDE OR 1-OXIDE  
L10 376085 S PHENOL? OR CRESOL?  
L11 0 S BIRTHER  
L12 6 S L8 AND L9-11  
L13 4 S L12 AND POLYMER?  
SELECT RN L13 1-4

FILE 'REGISTRY' ENTERED AT 13:14:11 ON 07 MAR 2003

L14 25 S E1-25

FILE 'HCAPLUS' ENTERED AT 13:14:17 ON 07 MAR 2003

L15 4 S L13 AND L14

FILE 'STNGUIDE' ENTERED AT 13:15:27 ON 07 MAR 2003

FILE 'HCAPLUS' ENTERED AT 13:17:02 ON 07 MAR 2003

L16 16833 S ?ORTHOPHOSPH?  
L17 12 S L16 AND L7  
L18 0 S L17 AND L10  
L19 0 S L17 AND POLYMER?  
L20 1 S L17 AND PURIFICATION/TI  
L21 0 S L17 AND ALUMINUM/TI  
L22 0 S L17 AND ALUMIN/TI  
L23 4 S L17 AND ALUMINUM  
L24 12 S L17 AND ?PHOSPH?  
L25 40045 S BIRT?  
L26 0 S L25 AND L17  
L27 1070 S L25 AND COMPOUND  
L28 49 S L25(5A)COMPOUND  
L29 6 S L28 NOT BIRTH  
L30 1 S US6458956/PN  
SELECT RN L30 1

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 07 MAR 2003

L31 4 S E26-29

FILE 'HCAPLUS' ENTERED AT 13:41:16 ON 07 MAR 2003

L32 1 S L30 AND L31

FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003  
 E INSULIN/CN  
 E INSULIN (HUMAN)/CN

L33 3 S E272,E32,E96  
 SELECT RN L33 1-3

L34 31 S E282-284/CRN

L35 6509 S "INSULIN"

L36 0 S L35 AND RT3/NTE

L37 0 S L35 AND "RT3"

L38 0 S L35 AND NTE/FS

L39 4027 S L35 AND NTE/FA

L40 0 S L39 AND "RT3"

L41 18 S "RT3"

L42 1 S L41 AND C15 H12 I3 N 04/MF

FILE 'CAPLUS' ENTERED AT 15:07:36 ON 07 MAR 2003

L43 1514 S L42

L44 82 S L43(L) (RRT OR RCT) /RL

L45 0 S L44 AND INSULIN

L46 35 S L43 AND INSULIN/IT

L47 2 S L46 AND CONJUG?

L48 60 S L43 AND INSULIN

L49 2 S L48 AND CONJUGAT?

L50 2 S L48 AND LINK?

L51 0 S L48 AND COVALENT?

L52 3 S L48 AND REACT?

=> s insulin and rt3  
 148504 INSULIN  
 1884 INSULINS  
 148539 INSULIN  
 (INSULIN OR INSULINS)

1262 RT3

L53 52 INSULIN AND RT3

=> s 153 and conjugat?

180905 CONJUGAT?

L54 1 L53 AND CONJUGAT?

=> d ti

L54 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

TI Rapid transient increase of biliary triiodothyronine excretion during short-term infusion of glucose and arginine in rats

=> d ab

L54 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AB Studies were carried out to est. the excretion of triiodothyronine by bile in groups of rats infused with glucose, arginine or glucose combined with various doses of insulin. Groups of about eight male Wistar Olac rats were anesthetized by pentobarbital and thin polyethylene tubings were inserted into bile duct and femoral vein. The bile was collected into pre-weighed glass vials which were changed every hour. The first one hour interval was considered as control and during the second hour the following i.v. infusions were applied: 1. 4 mL 30% glucose; 2. arginine

(80 mg/2.4 mL saline); 3. 4 mL 30% glucose contg. 62.5, 125, 250 or 500 mU **insulin**. In some groups cycloheximide (2.5 mg/kg) or somatostatin (20 .mu.g/kg) were used. The aliquots of bile were treated with .beta.-glucuronidase/arylsulfatase and the concn. of total (i.e., **conjugated** plus unconjugated) triiodothyronine was estd. by specific inhouse RIA. The results were expressed as ng/h and the vol. of bile was estd. by weighing the previously tared collection vials. Significant increase of biliary T3 excretion was found during the 60 min infusion of glucose or arginine. However, in fed rats such increase did not continue after the termination of infusion, while in fasted rats the increase was obsd. still for next 60 min after the infusion. The attempts to further stimulate the excretion of T3 by the addn. of small **insulin** doses (62.5, 125, 250 and 500 mU) to the infused glucose showed inversed effect: by such intervention the increase of T3 was blunted by higher doses, while at lower doses insignificant increase appeared. The increase of biliary T3 excretion was also blunted by cycloheximide (translation inhibitor) and somatostatin (**insulin** release inhibitor) both in normal fed and 24 h fasted rats. Thus, short-term i.v. infusion of glucose and arginine resulted in immediate and transient increase of biliary T3 excretion which was inhibited by both the cycloheximide and somatostatin. Taken together with the authors' previous findings, this supports the view on rapid fluctuation of hepatic iodothyronine metab. as related to preprandial (prevailing effect of gluconeogenic hormones resulting in preferential formation of **rT3** ) and postprandial period (predominant effect of **insulin** resulting in preferential formation of T3).

=> d his

(FILE 'HOME' ENTERED AT 13:09:05 ON 07 MAR 2003)

FILE 'HCAPLUS' ENTERED AT 13:09:24 ON 07 MAR 2003

L1 71 S WAGENBLAST G?/AU  
 L2 41 S SUTORIS H?/AU  
 L3 36 S SCHLIEPHAKE V?/AU  
 L4 1485 S SCHROEDER J?/AU  
 L5 1738 S KELLER H?/AU  
 L6 30 S JAWOREK T?/AU  
 L7 3348 S L1-6  
 L8 16 S L7 AND FREE RADICAL  
 L9 42391 S N-OXYL? OR N-OXIDE OR 1-OXIDE  
 L10 376085 S PHENOL? OR CRESOL?  
 L11 0 S BIRTHR  
 L12 6 S L8 AND L9-11  
 L13 4 S L12 AND POLYMERI?  
 SELECT RN L13 1-4

FILE 'REGISTRY' ENTERED AT 13:14:11 ON 07 MAR 2003

L14 25 S E1-25

FILE 'HCAPLUS' ENTERED AT 13:14:17 ON 07 MAR 2003

L15 4 S L13 AND L14

FILE 'STNGUIDE' ENTERED AT 13:15:27 ON 07 MAR 2003

FILE 'HCAPLUS' ENTERED AT 13:17:02 ON 07 MAR 2003

L16 16833 S PORTHOPHOSPH?  
 L17 12 S L16 AND L7

09/719, 423

L18 0 S L17 AND L10  
L19 0 S L17 AND POLYMER?  
L20 1 S L17 AND PURIFICATION/TI  
L21 0 S L17 AND ALUMINUM/TI  
L22 0 S L17 AND ALUMIN/TI  
L23 4 S L17 AND ALUMIUM  
L24 12 S L17 AND ?PHOSPH?  
L25 40045 S BIRT?  
L26 0 S L25 AND L17  
L27 1070 S L25 AND COMPOUND  
L28 49 S L25(5A) COMPOUND  
L29 6 S L28 NOT BIRTH  
L30 1 S US6458956/PN  
SELECT RN L30 1

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 07 MAR 2003  
L31 4 S E26-29

FILE 'HCAPLUS' ENTERED AT 13:41:16 ON 07 MAR 2003  
L32 1 S L30 AND L31

FILE 'REGISTRY' ENTERED AT 14:52:31 ON 07 MAR 2003  
E INSULIN/CN  
E INSULIN (HUMAN) /CN  
L33 3 S E272,E32,E96  
SELECT RN L33 1-3  
L34 31 S E282-284/CRN  
L35 6509 S "INSULIN"  
L36 0 S L35 AND RT3/NTE  
L37 0 S L35 AND "RT3"  
L38 0 S L35 AND NTE/FS  
L39 4027 S L35 AND NTE/FA  
L40 0 S L39 AND "RT3"  
L41 18 S "RT3"  
L42 1 S L41 AND C15 H12 I3 N 04/MF

FILE 'CAPLUS' ENTERED AT 15:07:36 ON 07 MAR 2003  
L43 1514 S L42  
L44 82 S L43(L) (RRT OR RCT) /RL  
L45 0 S L44 AND INSULIN  
L46 35 S L43 AND INSULIN/IT  
L47 2 S L46 AND CONJUG?  
L48 60 S L43 AND INSULIN  
L49 2 S L48 AND CONJUGAT?  
L50 2 S L48 AND LINK?  
L51 0 S L48 AND COVALENT?  
L52 3 S L48 AND REACT?  
L53 52 S INSULIN AND RT3  
L54 1 S L53 AND CONJUGAT?

=> s 153 and (link? or covalent? or react?)  
352651 LINK?  
79233 COVALENT?  
4107506 REACT?  
L55 7 L53 AND (LINK? OR COVALENT? OR REACT?)

=> d ti 1-7

L55 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Relationships between the structure of **insulin** and its physiological effects. Thyronine **insulin** analogues

L55 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Endocrine and metabolic responses in children with meningococcal sepsis: striking differences between survivors and nonsurvivors

L55 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness

L55 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Different short-term effect of protein and carbohydrate intake on TSH, growth hormone (GH), **insulin**, C-peptide, and glucagon in humans

L55 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Effect of the **sex-linked** dwarf gene on thyrotropic and somatotropic axes in the chick embryo

L55 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Hormonal control of a low Km (type II) iodothyronine 5'-deiodinase in cultured NB41A3 mouse neuroblastoma cells

L55 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Reduced and compensatory growth: endocrine and metabolic changes during food restriction and refeeding in steers

=> d kwic

L55 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Relationships between the structure of **insulin** and its physiological effects. Thyronine **insulin** analogues

AB The authors studied the biol. activity of **insulin** **covalently linked** to thyronines: N. $\alpha$ .B1-L-thyroxyl-**insulin** (T4-Ins) and N. $\alpha$ .B1-**rT3-insulin** (rT3-Ins). In vitro binding expts. using rat liver plasma membrane as a source of inulin receptor demonstrated that there were no significant differences between **insulin** and either of the analogs, indicating that the addn. of the thyroid moiety to the B1 position of **insulin** did not decrease the capacity for normal assocn. with the **insulin** receptor. The analogs also bound to thyroid hormone-binding proteins. In human subjects, T4-Ins displayed a significant relative hepatoselectivity with no. . .

ST thyronine **insulin** analog biol activity structure; thyroxine **insulin** analog biol activity structure; **rT3** **insulin** analog biol activity structure; reverse triiodothyronine **insulin** analog biol activity; liver selectivity thyronine **insulin** analog; adipose tissue thyronine **insulin** analog

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(thyroid hormone-binding; thyronine **insulin** analogs biol. activity in relation to structure)

IT Adipose tissue  
Human  
Liver  
Structure-activity relationship  
(thyronine **insulin** analogs biol. activity in relation to structure)

IT **Insulin receptors**  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thyronine **insulin** analogs biol. activity in relation to  
 structure)

IT 9004-10-8, **Insulin**, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (thyronine **insulin** analogs biol. activity in relation to  
 structure)

IT 496030-81-0 496030-82-1  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (thyronine **insulin** analogs biol. activity in relation to  
 structure)

=> s ?triiodothyronine?  
 L56 16982 ?TRIIODOTHYRONINE?

=> s 156 and insulin  
 148504 INSULIN  
 1884 INSULINS  
 148539 INSULIN  
 (INSULIN OR INSULINS)  
 L57 1569 L56 AND INSULIN

=> s 156 and 157  
 L58 1569 L56 AND L57

=> s 158 and conjugat?  
 180905 CONJUGAT?  
 L59 14 L58 AND CONJUGAT?

=> s 158 and conjugat?/it  
 73736 CONJUGAT?/IT  
 L60 5 L58 AND CONJUGAT?/IT

=> d ti 1-5

L60 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 TI Method for assaying biomolecules and other constituents using indicator  
 conjugates with synthetic nucleounits in lateral flow, liquid, and dry  
 chemistry techniques

L60 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 TI A CLA mixture prevents body triglyceride accumulation without affecting  
 energy expenditure in Syrian hamsters

L60 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 TI Preparation of controlled-size inorganic particles for use in separations,  
 assays, as magnetic molecular switches, and as inorganic liposomes for  
 medical applications

L60 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 TI Enzyme-linked immunoassay, assay kits and pair-binding compounds

L60 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 TI Tests for anterior pituitary gland function. II. Secretion of growth  
 hormone (GH, luteinizing hormone(LH), follicle-stimulating hormone(FSH),

09/719, 423

and thyroid-stimulating hormone (TSH)

=> s 1999:811275/an  
L61 1 1999:811275/AN

=> d ti

L61 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS  
TI Preparation of triiodothyronine derivative of insulin

=> select rn 161 1  
E285 THROUGH E287 ASSIGNED

=> file reg  
FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2003 HIGHEST RN 497140-34-8  
DICTIONARY FILE UPDATES: 6 MAR 2003 HIGHEST RN 497140-34-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s e285-287  
1 252848-50-3/BI  
(252848-50-3/RN)  
1 252878-45-8/BI  
(252878-45-8/RN)  
1 252878-62-9/BI  
(252878-62-9/RN)  
L62 3 (252848-50-3/BI OR 252878-45-8/BI OR 252878-62-9/BI)

=> d scan

L62 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin (human), NB-[O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-L-tyrosyl]-  
(9CI)  
SQL 52, 31, 21  
MF C272 H393 I3 N66 O80 S6  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


09/719,423

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L62 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Carbamic acid, [(1S)-2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1-[(4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl)methyl]-2-oxoethyl]-, 2-  
(methylsulfonyl)ethyl ester (9CI)  
MF C23 H21 I3 N2 O10 S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L62 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Insulin (human), NA-[{2-(methylsulfonyl)ethoxy]carbonyl]-29B-[N6-{[2-(methylsulfonyl)ethoxy]carbonyl}-L-lysine]- (9CI)  
SQL 51,30,21  
MF C265 H395 N65 O85 S8  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> d 1-2

L62 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS  
RN 252878-62-9 REGISTRY  
CN Insulin (human), NB-[O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-L-tyrosyl]- (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE  
MF C272 H393 I3 N66 O80 S6  
CI MAN

SR CA  
 LC STN Files: CA, CAPLUS

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
 1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L62 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS  
 RN 252878-45-8 REGISTRY  
 CN Insulin (human), NA-[[2-(methylsulfonyl)ethoxy]carbonyl]-29B-[N6-[[2-(methylsulfonyl)ethoxy]carbonyl]-L-lysine]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE  
 MF C265 H395 N65 O85 S8  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
 1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d sqide

L62 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS  
 RN 252878-62-9 REGISTRY  
 CN Insulin (human), NB-[O-(4-hydroxy-3,5-diodophenyl)-3-iodo-L-tyrosyl]- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE  
 SQL 52,31,21  
 NTE multichain  
 modified (modifications unspecified)

type	-----	location	-----	description
bridge		Cys-8	- Cys-7'	disulfide bridge
bridge		Cys-20	- Cys-20'	disulfide bridge
bridge		Cys-6'	- Cys-11'	disulfide bridge

SEQ 1 YFVNQHLCGS HLVEALYLVC GERGFFYTPK T

SEQ 1 GIVEQCCTSI CSLYQLENYC N

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C272 H393 I3 N66 O80 S6  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS  
 1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file caplus medline biosis embase  
FILE 'CAPLUS' ENTERED AT 15:24:46 ON 07 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:24:46 ON 07 MAR 2003

FILE 'BIOSIS' ENTERED AT 15:24:46 ON 07 MAR 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 15:24:46 ON 07 MAR 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s 252878-62-9  
L63 1 252878-62-9

=> d ti

L63 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS  
TI Preparation of triiodothyronine derivative of insulin

=> s insulin and (rt3 or ?triiodothyronin? )  
L64 6064 INSULIN AND (RT3 OR ?TRIIODOTHYRONIN? )

=> s l64 and conjugat?  
L65 39 L64 AND CONJUGAT?

=> d ti 1-5

L65 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Method for assaying biomolecules and other constituents using indicator  
**conjugates** with synthetic nucleounits in lateral flow, liquid, and  
dry chemistry techniques

L65 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI A CLA mixture prevents body triglyceride accumulation without affecting  
energy expenditure in Syrian hamsters

L65 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI **Conjugated** linoleic acid effects on circulating hormones,  
metabolites and lipoproteins, and its proportion in fasting serum and  
erythrocyte membranes of swine

L65 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Preparation of **triiodothyronine** derivative of **insulin**

L65 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Rapid transient increase of biliary **triiodothyronine** excretion  
during short-term infusion of glucose and arginine in rats

=> d ti 6-39

L65 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Effect of passive immunization against somatostatin using a high-affinity  
antisera on growth, IGF-I and thyroid hormone levels in neonatal lambs  
reared under warm or cold environmental conditions

L65 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Preparation of controlled-size inorganic particles for use in separations, assays, as magnetic molecular switches, and as inorganic liposomes for medical applications

L65 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Hormonal changes following an acute stress in control and somatostatin-immunized pigs

L65 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin **conjugates**

L65 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Enzyme-linked immunoassay, assay kits and pair-binding compounds

L65 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects of glucose, glucagon, and **insulin**

L65 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Immunological dosage by fixed enzyme

L65 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Tests for anterior pituitary gland function. II. Secretion of growth hormone (GH, luteinizing hormone(LH), follicle-stimulating hormone(FSH), and thyroid-stimulating hormone(TSH)

L65 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI The effect of undernutrition and other factors on the development of glucuronyl transferase activity in the newborn rabbit

L65 ANSWER 15 OF 39 MEDLINE  
TI A CLA mixture prevents body triglyceride accumulation without affecting energy expenditure in Syrian hamsters.

L65 ANSWER 16 OF 39 MEDLINE  
TI **Conjugated** linoleic acid effects on circulating hormones, metabolites and lipoproteins, and its proportion in fasting serum and erythrocyte membranes of swine.

L65 ANSWER 17 OF 39 MEDLINE  
TI Rapid transient increase of biliary **triiodothyronine** excretion during short-term infusion of glucose and arginine in rats.

L65 ANSWER 18 OF 39 MEDLINE  
TI The effect of interleukin-2 on suppressor T lymphocytes in autoimmune thyroid disease.

L65 ANSWER 19 OF 39 MEDLINE  
TI [Human physiological blood protection systems in the late periods after ionizing radiation exposure related to the accident at the Chernobyl Atomic Electric Power Station].  
Sostoianie fiziologicheskikh zashchitnykh sistem krovi cheloveka v otdalennye periody posle vozdeistvia ioniziruiushchey radiatsii, sviazannoi s avariei na Chernobyl'skoi AES.

L65 ANSWER 20 OF 39 MEDLINE  
TI Hormonal changes following an acute stress in control and somatostatin-immunized pigs.

L65 ANSWER 21 OF 39 MEDLINE  
TI Characterization of differentiated Syrian golden hamster pancreatic duct cells maintained in extended monolayer culture.

L65 ANSWER 22 OF 39 MEDLINE  
TI Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin **conjugates**.

L65 ANSWER 23 OF 39 MEDLINE  
TI Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects of glucose, glucagon, and **insulin**.

L65 ANSWER 24 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI **Conjugated** linoleic acid effects on circulating hormones, metabolites and lipoproteins, and its proportion in fasting serum and erythrocyte membranes of swine.

L65 ANSWER 25 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI Hormonal concentrations during parturition in sows immunized against somatostatin.

L65 ANSWER 26 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI Effect of passive immunization against somatostatin using a high-affinity antiserum on growth, IFG-I and thyroid hormone levels in neonatal lambs reared under warm or cold environmental conditions.

L65 ANSWER 27 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI Some physiological protective blood systems in long-term follow-up after the exposure to ionizing radiation due to the Chernobyl accident.

L65 ANSWER 28 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI Growth and serum thyroid hormone and **insulin**-like growth factor I (IGF-I) responses to natural passive immunization against somatostatin in the lamb.

L65 ANSWER 29 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI HORMONAL CHANGES FOLLOWING AN ACUTE STRESS IN CONTROL AND SOMATOSTATIN-IMMUNIZED PIGS.

L65 ANSWER 30 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI CHARACTERIZATION OF DIFFERENTIATED SYRIAN GOLDEN HAMSTER PANCREATIC DUCT CELLS MAINTAINED IN EXTENDED MONOLAYER CULTURE.

L65 ANSWER 31 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI EPIDERMAL GROWTH FACTOR-DEPENDENT GROWTH OF HUMAN KB CELLS IN A DEFINED MEDIUM AND ALTERED GROWTH FACTOR REQUIREMENTS OF KB MUTANTS RESISTANT TO EGF PSEUDOMONAS EXOTOXIN **CONJUGATES**.

L65 ANSWER 32 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI SELECTION FOR HIGH AND LOW LEVEL OF 5-ALPHA ANDROST-16-EN-3-ONE IN BOARS I. DIRECT AND CORRELATED RESPONSE OF ENDOCRINOLOGICAL TRAITS.

L65 ANSWER 33 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI LIPO PROTEIN LIPASE EC-3.1.1.34 CONTENT IN OB-17 PREADIPOCYTES DURING

09/719, 423

ADIPOSE CONVERSION IMMUNO FLUORESCENT LOCALIZATION OF THE ENZYME.

L65 ANSWER 34 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI THYROID HORMONE METABOLISM IN PRIMARY CULTURED RAT HEPATOCYTES EFFECTS OF GLUCOSE GLUCAGON AND **INSULIN**.

L65 ANSWER 35 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
TI A CLA mixture prevents body triglyceride accumulation without affecting energy expenditure in Syrian hamsters.

L65 ANSWER 36 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
TI **Conjugated** linoleic acid effects on circulating hormones, metabolites and lipoproteins, and its proportion in fasting serum and erythrocyte membranes of swine.

L65 ANSWER 37 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
TI Rapid transient increase of biliary **triiodothyronine** excretion during short-term infusion of glucose and arginine in rats.

L65 ANSWER 38 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
TI Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-pseudomonas exotoxin **conjugates**.

L65 ANSWER 39 OF 39 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
TI Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects of glucose, glucagon, and **insulin**.

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 15:28:51 ON 07 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Feb 28, 2003 (20030228/UP).